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Abnormal scarring and its accompanying cosmetic, functional and psychological burden is 
a major challenge in modern medicine. Pathological scars such as hypertrophic scars or 
keloids present cutaneous conditions characterized by excessive collagen deposition which 
can be itchy and painful, causing serious functional and aesthetical disabilities. The crucial 
role of myofibroblasts and transforming growth factor-beta (TGF-β) signaling in the 
pathogenesis of fibrosis and, thus, scarring, is widely accepted. Nevertheless, effective 
preventive or therapeutic strategies are still not available despite extensive research. 
Autologous fat grafting is a novel approach leading to partly significant improvements of 
scar tissue regarding functionality and appearance. Here, fat is harvested from body 
deposits and re-injected into areas with scarred tissue. Since adipose tissue does not only 
contain adipocytes but is a source for adipose-derived stem cells (ASCs) and even more 
cell types, various origins for the observed scar regeneration are conceivable. Regenerative 
effects from adipocytes or ASCs are discussed, however, the underlying mechanism is still 
unknown. Aiming to unravel the regenerative potential of adipose tissue, paracrine effects 
of ASCs and adipocytes on in vitro differentiated myofibroblasts and fibroblasts from 
hypertrophic scars were investigated. Interestingly, following incubation with adipocyte-
conditioned medium, the expression of the myofibroblast marker α-smooth muscle actin 
and the extracellular matrix components collagen 1 and 3 decreased significantly indicating 
a myofibroblast reprogramming. Secretome analysis, ELISA, Western blot and high 
throughput protein analysis indicate a pivotal role of BMP-4 secreted by adipocytes in the 
cellular reprogramming. In addition, direct as well as indirect activation of peroxisome 
proliferator-activated receptor (PPAR)γ signaling was shown after application of conditioned 
medium from adipocytes. Remarkably, speculations about a reciprocal, antagonistic 
relationship between PPARɣ and TGF-β do exist which might indicate anti-fibrotic effects 
on the part of PPARɣ. Although a myofibroblast-to-adipocyte transition was hypothesised, 
myofibroblasts trans-differentiation, however, was not observed. 
Overall, adipocytes induce myofibroblast reprogramming via BMP-4 secretion and by direct 
as well as indirect activation of PPARγ signaling. These findings highlight the regenerative 
potential of adipocytes on scar tissue and may pave the way for novel therapeutic strategies 






Eine überschießende Wundreaktion und eine damit einhergehende Narbenbildung stellt 
betroffene Patienten nicht nur vor ästhetische Herausforderungen, sondern bedingt meist 
auch schmerzhafte, funktionelle Einschränkungen. Zugrundeliegende Mechanismen 
weisen auf eine zentrale Rolle von Myofibroblasten sowie des transforming growth factor-
beta (TGF-β) Signalwegs hin. Zur Behandlung von hypertrophen Narben und Keloiden 
existieren eine Vielzahl invasiver als auch non-invasiver Methoden; jedoch liefert bisher 
keine dieser Behandlungsmöglichkeiten zufriedenstellende und ausreichend wirkungsvolle 
Ergebnisse. Eigenfetttransplantationen bieten eine neue Alternative und zeigen 
vielversprechende Verbesserungen des Narbengewebes hinsichtlich Histologie und 
Funktionalität. Die zugrundeliegenden Mechanismen dieser Effekte sind bislang 
weitestgehend unbekannt, obwohl den Fettgewebsstammzellen (adipose-derived stem 
cells, ASCs) und Adipozyten ein regeneratives Potenzial attestiert wird. Um dieses 
Potenzial hinsichtlich einer Narbenregeneration näher herauszustellen, wurden parakrine 
Effekte von beiden Zelltypen auf Myofibroblasten sowie auf Fibroblasten aus hypertrophem 
Narbengewebe untersucht. Dabei zeigte sich interessanterweise, dass der 
Myofibroblastenmarker α-smooth muscle actin (α-SMA) und die extrazellulären 
Matrixproteine Kollagen 1 und 3 signifikant reduziert waren, nachdem die Zellen zu 
konditioniertem Medium von Adipozyten exponiert wurden. Weitere Analysen inklusive 
einer Sekretomanalyse, Western Blot, ELISA sowie einer high-throughput-Proteinanalyse 
ergaben eine Schlüsselrolle des bone morphogenetic proteins (BMP)-4, welches von 
Adipozyten sezerniert wird, und entscheidend für die beobachtete Umprogrammierung der 
Myofibroblasten zu sein scheint. Zusätzlich kristallisierte sich der Peroxisom-Proliferator-
aktivierte Rezeptor gamma (PPARγ) als wichtig heraus, dessen vermehrte Expression 
ebenfalls durch Zugabe von konditioniertem Adipozyten-Medium beobachtet wurde. 
Bemerkenswert ist, dass zwischen PPARγ und TGF-β Signalwegen eine reziproke, 
antagonistische Beziehung zu bestehen scheint, welche auf anti-fibrotische Effekte seitens 
PPARγ deutet.  
Insgesamt induzierten Adipozyten eine Umprogrammierung von Myofibroblasten, welche 
durch BMP-4-Sekretion sowie PPARγ-Aktivierung erfolgte. Diese Ergebnisse heben die 
entscheidende Rolle von Adipozyten in der Narbenregeneration hervor und könnten für 
zukünftige Therapieansätze in der Prävention bzw. Behandlung hypertropher Narben 
nützlich sein. 
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1.1. Skin Fibrosis 
Fibrosis is the process of excessive connective tissue formation affecting a plethora of 
tissues and organs thereby disrupting their normal organ architecture, eventually leading to 
organ failure. Fibrotic processes can be caused by multi-system diseases such as systemic 
sclerosis (SSc) or nephrogenic systemic fibrosis but also affect specific organs including 
the lung, kidney, liver, heart or bladder. Although the underlying mechanisms are quite 
diverse, they all have distinct characteristics in common. Virtually every organ in the human 
body can be affected by physiological or pathological fibrotic processes (Wynn, 2008). 
Especially the human skin represents an organ where normal and abnormal fibrotic 
responses lie very close together. As the primary barrier, the skin protects the human body 
against physical injuries, pathogens or other potential hazards. Therefore, the skin is an 
intricate structure comprising various layers, each with multiple functions. In the epidermis, 
the upper layer, keratinocytes are the major residing cell type. Its barrier function and the 
protection against trans-epidermal water loss are the most important epidermal attributes. 
The layer below, the dermis, provides nutrients to the non-vascularized epidermis. Here, 
fibroblasts alongside with collagenous and elastic fibers are found, ensuring skin elasticity 
and strength. In addition to the dermis and epidermis, which together form the cutis, there 
is a subcutaneous layer where fat depots are located for energy storage and thermal 
insulation. Moreover, this highly vascularized structure provides oxygen and nutrient supply 
to the upper skin layers. When injured, the skin must repair itself rapidly to sustain 
cutaneous integrity. Therefore, the skin presents a fascinating cascade of repair responses 
(Gurtner et al., 2008). However, these mechanisms are prone to aberrations and may lead 
to skin fibrosis, and abnormal scars such as hypertrophic scars and keloids can occur. 
1st1st1st Hypertrophic Scars and Keloids: Appearance and Treatment 
Abnormal scarring and its accompanying cosmetic, functional and psychological burden is 
a major challenge in modern medicine. Up to 30% of elective surgeries are followed by 
aberrations in physiological wound healing, resulting in hypertrophic scarring or keloid 
formation (Mokos et al., 2017, Hoerst et al., 2019). Typically, tissue repair, beginning after 
a skin injury, ultimately results in a scar which never obtains the flexibility or strength of the 
original tissue. Therefore, scars are considered as the end point of mammalian tissue repair 
(Bayat et al., 2003). Ideally, tissue repair would result in total regeneration with the repaired 
tissue having the same structural and functional characteristics as the uninjured skin. So 
far, scarless healing is only observed in mammalian embryos as well as in lower 






(Suzuki et al., 2005, Brockes and Kumar, 2002). For axolotl and Xenopus froglets it is known 
that their entire skin, including secretory appendages, regenerates after a full-thickness 
injury. Even the skin pigmentation pattern can be restored. In contrast, adult mammalian 
wound healing processes challenge to obtain such regeneration (Gurtner et al., 2008). 
Scars are often considered as trivial but in fact, scars can place a high burden on patients 
and potentially come along with disfiguring and aesthetical issues. Indeed, scars can cause 
severe itching, tenderness, pain, sleep disturbance, anxiety, depression, and disruption of 
daily activities. Together with other psychological liabilities such as post-traumatic stress 
reactions or loss of self esteem, scarring may lead to a reduced quality of life (Bayat et al., 
2003).  
Skin tissue repair results in a broad range of scar types. Five main types of scars can be 
divided, starting with a 'normal' fine line and continuing with widespread and atrophic scars, 
scar contractures and raised scars. All these scars have a different clinical appearance, 
etiology and pathogenesis, therefore requiring different therapeutic approaches (Bayat et 
al., 2003). Raised scars are caused by excessive extracellular matrix (ECM) deposition and 
can be further classified into hypertrophic scars and keloids. Although there are similarities 
between both types of scars, there are also some clinical, histological and epidemiological 
differences (Fig. 1). Hypertrophic scars are raised scars that remain within the boundaries 
of the original lesion. They occur 4 to 8 weeks after dermal injury, have a rapid growth phase 
of up to 6 months and eventually regress with time (Wheeland, 1996). These scars are often 
red, firm, itchy and painful. Typically, hypertrophic scars occur after extensive trauma such 
as deep burns or even standard surgeries. Commonly, hypertrophic scarring develops in 
areas with high tension such as shoulders, neck, prosternum or ankles (Gauglitz et al., 
2011).  
Different to hypertrophic scars, keloids are raised scars that spread beyond the margins of 
the original wound. They invade the surrounding normal skin and often continuously grow. 
Keloids may appear years after a minor injury or even develop spontaneously. Keloids are 
very site specific with examples of the ear lobe or cheeks, and it happens that they invariably 
reoccur after excision (Rockwell et al., 1989). Usually, keloids do not regress spontaneously 
after time and are unique to humans (Leventhal et al., 2006). Keloids appear to be inflamed, 








Fig. 1: Morphological differences between hypertrophic scars and keloids.  
Hypertrophic scars show excessive collagen deposition and numerous myofibroblasts. In contrast, 
keloids extent beyond the boundaries of the original lesion and contain thick, disorganized collagen 
bundles. Myofibroblasts are only rarely seen in keloids and blood vessels are occluded. Modified 
from a template kindly provided by Anna Löwa. 
 
In addition to that, there are also histological differences between hypertrophic and keloid 
scars. Both scar types contain an overabundance of dermal collagen, but hypertrophic scars 
contain primarily collagen 3 which is organized in bundles parallel to the epidermis (Gauglitz 
et al., 2011). Characteristic for hypertrophic scars, abundant nodules containing 
myofibroblasts are being observed. Contrary to hypertrophic scars, keloids are composed 
of disorganized collagen 1 and 3 without nodules of myofibroblasts (Slemp and Kirschner, 
2006). The presence of myofibroblasts, specialized fibroblasts which are alpha-smooth 
muscle actin (α-SMA)-positive, in hypertrophic scars would explain the observed 
contraction seen in hypertrophic scars but not in keloids (Junker et al., 2008). However, 
using myofibroblasts and its marker to distinguish between both scar types is currently re-
discussed as this protein seems to be expressed under both conditions (Lee et al., 2004). 
Both hypertrophic and keloid scars have an equal sex distribution and predominantly occur 
in the second to third decade of patient’s life. The incidence for hypertrophic scars is with 
up to 91% highest after burn injuries followed by incidence rates of 40 to 70% after injuries, 






observed in all races with dark-skinned individuals being more prone to keloid formation 
(incidence of 6 to 16% in African populations) (Cosman et al., 1961). A genetic 
predisposition for keloid occurrence is being discussed since patients with keloids often 
describe a positive family history in contrast to those with hypertrophic scars (Gauglitz et 
al., 2011). 
Both scar types are major therapeutic challenges for surgeons and dermatologists. 
Although there exists a wide range of treatment options, none of these is efficient and 
optimal (Marshall et al., 2018). In general, non-invasive and invasive procedures need to 
be distinguished. Non-invasive therapies include the use of compression therapy such as 
pressure garments with or without gel sheeting (O’Brien and Jones, 2013). Also, acrylic 
casts, masks and clips or various oils, lotions and creams are applied. In addition, silicone 
sheeting is a popular option (Fulton Jr, 1995). More invasive treatments include surgical 
excision or intralesional corticosteroid injection. Other treatments with variable results 
involve injections of fluorouracil, bleomycin or interferon gamma, radiotherapy, laser therapy 
and cryosurgery (Rabello et al., 2014). One option is also the leave alone management. 
Occasionally, scars are best left undisturbed especially after invasive treatment. This can 
take up to one year until further treatment options can be considered by the scar’s 
appearance (Bayat et al., 2003). Therapeutics based on molecular targets have not yet 
been beyond clinical trial but are expected longingly (Friedman 2013).  
1.1.2. Wound Repair Mechanisms 
Much of the research focus on pathological scarring includes the attempt for a better 
understanding of the cellular and molecular processes involved in wound healing 
processes. These repair mechanisms include a series of dynamic and physiological 
processes involving various cell types, matrix molecules, cytokines and mediators (Gurtner 
et al., 2008). In general, wound healing is divided into three overlapping phases: 
inflammation, proliferation and remodeling/maturation (Fig. 2).  
Triggered by a deep tissue injury or damage, the inflammatory response phase is initiated. 
Platelet aggregation forms a hemostatic plug and blood coagulation provides a first 
provisional matrix (Baum and Arpey, 2005). This matrix, mainly composed of fibrin and 
fibronectin, fills the tissue defect and enables effector cell influx as well as cell migration by 
acting as a scaffold. Platelets release multiple cytokines thereby recruiting inflammatory 
cells: at the early stage of an acute inflammation granulocytes are the predominant 
infiltrating leucocytes, later replaced by monocyte infiltration (Werner and Grose, 2003). 
Monocytes differentiate into phagocytic macrophages ensuring debris removal. Following 







Fig. 2: The three classical stages of wound healing.  
Inflammatory phase: wound after 24h to 48h of injury. The wound bed is characterized by a fibrin clot 
with abundant bacteria, neutrophils and platelets. Proliferative phase: depicted is a wound 5-10 days 
after injury where an eschar (scab) has been formed on the wound surface. New blood vessels now 
appear, and keratinocytes migrate under the eschar. Granulation tissue has replaced the fibrin clot. 
Maturation phase: this phase can last up to one year or longer. Disorganized collagen has been laid 
down by fibroblasts. The re-epithelialized wound is slightly higher than the surrounding skin and 






These include proteases and oxygen derived free radicals for tissue destruction, cytokines 
and chemokines for chemotaxis, thromboxane A2 and prostaglandins involved in vascular 
hemodynamics plus a plethora of growth factors as well as matrix metalloproteinases 
(MMPs) responsible for fibrogenesis (Singer, 1999, Werner and Grose, 2003). Therefore, 
the inflammatory phase serves, besides the removal of bacteria and debris, to prepare the 
wound bed for repair. Usually 72h after injury, the inflammatory response diminishes, and 
the wound healing process shifts towards the proliferative phase (Gurtner et al., 2008). 
The proliferative phase takes place on day 2 to 10 after injury with the major attempt to 
generate granulation tissue which replaces the provisional matrix. This phase includes 
several processes that partially cross and work together, which are namely re-epithelization, 
angiogenesis and fibrogenesis for granulation tissue development. The process of re-
epithelialization begins just hours after injury and continues during inflammatory and 
proliferative phase. Keratinocytes begin to migrate from the wound edge and local hair 
follicles, and advance across the wound surface until they reach keratinocytes from the 
other wound site (Raja et al., 2007). Especially in larger wounds, proliferation of 
keratinocytes is important as well, in order to close the wound defect sufficiently (Coulombe, 
2003, Baum and Arpey, 2005). In addition, keratinocytes secrete a variety of growths factors 
stimulating fibrogenesis and angiogenesis in the parts below, these include transforming 
growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), epidermal growth 
factor (EGF) and keratinocyte growth factor (KGF) (Werner and Grose, 2003). Another 
critical factor in the ongoing wound healing process is angiogenesis. Adequate blood supply 
is important for the granulation tissue being formed providing nutrient delivery and support 
for fibroblast migration. Endothelial cells in local uninjured capillaries migrate into the wound 
bed and form tubules that mature into new capillaries (Li et al., 2003). A wide range of pro-
angiogenetic factors is being released at the site of injury facilitating this new vascularisation 
with TGF-β1, angiopoietin and VEGF representing one of the most important factors (Li et 
al., 2003). Primary responsible for the development of granulation tissue are fibroblasts, 
representing the key cell type in this wound healing phase. Fibroblasts move into the 
provisional matrix as a basis for fibrogenesis, serving as the main source for ECM proteins 
such as collagens, glycosaminoglycans or proteoglycans (Bainbridge, 2013). These ECM 
proteins constitute the newly formed granulation tissue thereby providing structural integrity 
to the wound. In addition to ECM deposition, fibroblasts differentiate into so-called 
myofibroblasts which provide force for wound contraction, thereby contributing to wound 
closure (Hinz, 2007). Also, they secrete MMPs and their inhibitors (tissue inhibitor of 
metalloproteinases, TIMPs) and hence, are in involved in granulation tissue remodeling 






Up to 2 to 3 weeks after injury, the tissue defect has been closed by granulation tissue and 
is covered with new epithelial cells. The wound area is now comprised of a widely acellular 
mass with disorganized collagen fibers and other ECM proteins. There are no dermal 
appendages such as hair follicles or sweat glands. The wound surface contracted, which is 
the reason for the wound base to be wider than the surface (Marshall et al., 2018). Most of 
the cells that entered the wound bed initially, like fibroblast, macrophages and endothelial 
cells, disappear via apoptosis or move away from the wound area (Gurtner et al., 2008). On 
this occasion, a process called remodeling or maturation begins and eventually lasts for 
months to years. During this phase, the collagen matrix is subject to a continuous 
remodeling especially by MMPs and TIMPs. Progressively, collagen 3, the main component 
of granulation tissue, is replaced by collagen 1, the major ECM protein found in the dermis 
(Monaco and Lawrence, 2003). This new collagen is more oriented and reorganized into a 
structurally sound lattice based on glycosaminoglycans and proteoglycans. Elastin, usually 
absent in granulation tissue, appears again and contributes to skin elasticity (Gurtner et al., 
2008). The resulting scar reaches a maximum tensile strength up to 80% of the original skin 
and often manifests less pigmented due to lacking hair follicles containing melanocyte stem 
cells (Levenson et al., 1965, Baum and Arpey, 2005). 
Even if the wound healing process includes a highly coordinated succession of events, 
however, it is prone to aberrations and may escape the controlled regulatory system. These 
abnormal repair mechanisms result in impaired remodelling of the granulation tissue leading 
for example to hypertrophic scarring in cutaneous repair or to fibrosis of internal organs 
such as lung, liver and kidney. During these fibrotic conditions, an excessive, uncontrolled 
accumulation of ECM proteins is observed with functional tissue being replaced by non-
functional fibrotic tissue (Wynn, 2008). At the cellular level, the continued presence of 
myofibroblasts in fibrotic tissues is broadly accepted as the main effector of fibrosis 
(Biernacka et al., 2011). Myofibroblasts removal or loss by apoptosis is normally considered 
as the transition between granulation tissue and healing or normal scar formation 
(Desmouliere et al., 1995). However, these cells persist in fibrotic lesions and are believed 
to be relevant for excessive collagen production leading to alterations of tissue architecture 
(Hinz, 2016). 
1.1.3. Myofibroblast Formation and Function 
Although the mechanisms of wound healing are not completely understood so far, it has 
become clear that fibroblasts and myofibroblasts play a critical role during this process. 
Especially the highly coordinated contraction of myofibroblasts is believed to be responsible 






myofibroblast activity is believed to cause abnormal scar formation, insights into 
myofibroblasts generation and their characterization is essential (Desmoulière et al., 2005). 
Phenotypically, myofibroblasts are an intermediate cell type between fibroblasts and 
smooth muscle cells. They exhibit ultrastructural features of fibroblasts with a spindle shape, 
prominent cytoplasmic projections and an abundant rough endoplasmic reticulum. Like 
smooth muscle cells, myofibroblasts have longitudinal cytoplasmic bundles of 
microfilaments and multiple nuclear membrane folds (Serini and Gabbiani, 1999). 
Due to the high demand for contractile cells in wound healing processes, myoﬁbroblasts 
can originate from various cell types. In skin repair, myofibroblasts are believed to originate 
mainly from local dermal fibroblasts but pericytes and vascular smooth muscle cells are also 
potential sources, especially during vascular wound healing (Rajkumar et al., 2005). In 
addition, there is evidence that myofibroblasts come from tubular epithelial cells through 
epithelial-mesenchymal transition (EMT) (Krenning et al., 2010). More recently, it came up 
that a similar process is possible with endothelial cells, termed endothelial-mesenchymal 
transition (EndMT) (Zeisberg et al., 2007). Also, the recruitment of fibroblast precursor cells 
(fibrocytes) from the bone marrow is seen as a potential source for myofibroblasts (Abe et 
al., 2001). The classical view of myofibroblasts originating from local quiescent fibroblasts, 
which is still believed to be the major myofibroblast source, was the object of several studies 
which revealed the transformation as a two-step process (Desmoulière et al., 2005, 
Tomasek et al., 2002) (Fig. 3). 
First, fibroblasts evolve into proto-myofibroblast in early granulation tissue 2-4 days after 
wounding. Such cells exert tractional force and may be induced by mechanical stress. The 
proto-myofibroblast is characterized by stress fibers which only contain β- and ɣ- 
cytoplasmic actins as well as by the expression of cellular fibronectin including the splice 
variant ED-A (Tomasek et al., 2002). The switch from the proto-myofibroblast to the 
differentiated myofibroblast has been connected to the production of TGF-β by inflammatory 
cells, the most accepted stimulator of myofibroblast differentiation. The action of TGF-β is 
related to the local presence of ED-A fibronectin (Tomasek et al., 2002). Therefore, 
myofibroblast differentiation depends both on a cell product and an ECM component. The 
transition into myofibroblasts is characterized by de novo expression of α-smooth muscle 
actin (α-SMA) (Hinz, 2007). Incorporation of α-SMA into stress fibers enhances the 
contractile activity of myofibroblasts thereby providing the cell’s most important 









Fig. 3: Myofibroblast differentiation as a 2-step process. 
First, fibroblasts differentiate into proto-myofibroblasts characterized by stress fibers which contain 
β- and γ- cytoplasmic actins. Due to the presence of TGF-β1 and the splice variant ED-A fibronectin, 
proto-myofibroblasts convert into differentiated myofibroblasts known for their alpha-smooth muscle 
actin (α-SMA expression). If a reversion of myofibroblasts back into fibroblasts is possible, is 
speculated. (Hinz 2008) 
 
Besides α-SMA, the most reliable myofibroblast marker, other distinctive and unique factors 
for myofibroblasts are difficult to name. One promising target is the expression of specific 
cadherins, cell-cell adhesion proteins linked to the intracellular actin skeleton. Proto-
myofibroblast in the early granulation tissue do express N-cadherin which makes them 
easily distinguishable from cadherin-negative dermal fibroblasts. In differentiated 
myofibroblasts, N-cadherin becomes replaced by OB-cadherin, playing an important role in 
coordination of contraction. However, since OB-cadherin is expressed in a variety of cell 
types with mesenchymal origin, it can not be considered as a unique marker for 
myofibroblasts (Hinz et al., 2004, Hinz, 2007). Desmin, an intermediate filament protein 
normally expressed in muscle cells, has been taken into account as a negative marker for 
myofibroblasts. Even so, in some pathological conditions of scarring, myofibroblast were 
found to be desmin-positive (Skalli et al., 1989). Other markers tested as myofibroblasts 
characteristic were not reliable as to inconsistent staining results such as for the fibroblast-






from other cell types with similar cytoskeletal features, especially smooth muscle cells and 
pericytes (Hinz, 2007).  
The contraction, myofibroblasts are known for, is based on a contractile apparatus known 
as the fibronexus. The fibronexus is a specialized adhesion complex which links bundles of 
actin to extracellular fibronectin domains via integrins. This linkage enables the fibronexus 
as a mechano-transduction system transmitting the force generated by stress fibers to the 
surrounding ECM (Tomasek et al., 2002, Hinz, 2007). In addition to its contractile features, 
myofibroblasts synthesise ECM proteins, notably collagen types I-VI, glycoproteins and 
proteoglycans (Schűrch et al., 2006). Also, myofibroblasts secrete many other matrix 
molecules such as laminin and thrombospondin as well as MMPs and TIMPs (Powell et al., 
1999). 
For many years, myofibroblasts were considered as terminally differentiated cells and that 
they would, most likely via apoptosis, disappear after wound contraction and closure was 
performed in physiological wound healing (Desmouliere et al., 1995, Hinz, 2007). However, 
more and more evidence come up that myofibroblasts become deactivated or revert to a 
more normal phenotype in designated situations (Hecker et al., 2011, Wettlaufer et al., 
2016). The question of the reversibility of myofibroblast differentiation is essential, 
particularly for fibrotic conditions where myofibroblast are involved. Given that myofibroblast 
appearance and dysfunction has severe consequences, knowledge about their 
development, function and survival is crucial (Hoerst et al., 2019). By this, not only 
myofibroblasts are in the research focus but also TGF-β signaling with its pivotal role in 
myofibroblast generation. 
1st1st4th TGF-β as a Profibrotic Mediator 
The TGF-β superfamily is composed of several growth factors that play major roles in 
physiological and pathological processes including cellular development and differentiation, 
embryogenesis, inflammatory response mechanisms and tissue repair (Shi and Massagué, 
2003, Ten Dijke et al., 2002). Indeed, the TGF-βs are one of the most pleiotropic and 
multifunctional growth factors known so far. The superfamily can be divided into the 
TGF/Activin/Nodal subfamily and the bone morphogenetic protein (BMP)/growth 
differentiation factor (GDF) subfamily with both subgroups activating distinct intrinsic 
pathways. There exist three isoforms of TGF-β in mammals, namely TGF-β1, TGF-β2 and 
TGF-β3, encoded by three different genes. Although the expression of the different isoforms 
is greatly tissue specific, all three function through the same cell surface receptor and affect 
similar cellular targets. TGF-β1 is the most common isoform with a ubiquitous expression 






isoforms are more tissue specific and limited to defined areas. Even if all three isoforms are 
involved in fibrotic processes, the main impact on fibrosis is attributed to TGF-β1 (Biernacka 
et al., 2011). Usually, TGF-β1 is an inactive latent complex with a C-terminal mature peptide 
and a N-terminal latency-associated peptide (LAP) (Munger et al., 1997). While LAP is 
bound to the mature peptide, the binding to its receptor is not possible. Before TGF-β1 is 
secreted by cells, the LAP is cleaved (Yang et al., 2007b). However, the mature peptide 
remains inactive since the LAP remains attached by a large latent complex (LLC). This 
complex still shields TGF-β1’s active epitope and prevents the interaction to its receptor. In 
connective tissue, the LLC is bound to ECM proteins such as elastin fibrils. Therefore, there 
are typically significant amounts of latent TGF-β1 stored in the matrix waiting to be activated 
if TGF-β1 signaling needs to be initiated (Todorovic et al., 2005). For activation of TGF-β1 
signaling, the LLC must be deliberated from the matrix by several proteases including 
plasmin, mast cell chymase and thrombin (Annes et al., 2003). Also, the interaction between 
TGF-β1 and LLC needs to be disrupted, a process that is so far poorly understood but 
believed to be protease-dependent (Biernacka et al., 2011).  
Active TGF-β1 binds to and phosphorylates the transmembrane TGF receptor type II (Fig. 
4). Upon ligand binding, type I receptor is recruited and forms a heterodimeric complex with 
the type II receptor, thus enabling a serine/threonine kinase activity. In mammals, there are 
seven different type I receptors termed ALK 1-7 (activin receptor-like) with ALK-5 being the 
most important one regarding fibrotic processes (Rahimi and Leof, 2007). The canonical 
TGF-β1 signaling pathway involves the Smad family of transcriptional activators. The eight 
Smad proteins can be divided into three functional groups: the receptor activated Smads 
(1, 2, 3, 5, 8), the common mediator Smad4 and inhibitory Smads (6, 7). It is generally 
accepted that the TGF‐β/Activin/Nodal subfamily activates Smad2 and 3, whereas the 
BMP/GDF subfamily signals through Smad1, 5 and 8 (ten Dijke and Hill, 2004). Smad 
activation is conducted through phosphorylation by the specific type I receptor depending 
on the cell type. For instance, Smad2 and 3 are usually triggered by ALK-5. Activated 
Smads form a complex with Smad4, translocate into the nucleus and induce the expression 
of specific target genes by cooperating with DNA transcription factors (Feng and Derynck, 
2005). Alternatively, gene expression can be regulated Smad independently via the non-
canonical signaling pathway (Fig. 4). Here, members of the mitogen-activated protein 
kinase (MAPK) family possess serine/threonine kinases and respond to external stimuli by 
activating a signaling cascade inducing differentiation, cell survival or apoptosis (Gaestel, 
2016). All three known MAPK pathways may be triggered by TGF-β1: extracellular signal-
regulated kinase (ERK), p38 MAPK and c-Jun-N-terminal kinase (JNK). Signaling through 
those pathways may also regulate Smad proteins but rather exert Smad independent 







Fig. 4: Canonical and non-canonical TGF-β signaling. 
Upon TGF- binding, the receptor type I and II (TGFR1/2) become phosphorylated. Subsequent Smad 
2/3 activation leads to a complex formation with Smad 4, translocation into the nucleus and target 
gene induction (α-SMA, PAI-1). TGF exerts its functions also Smad independent by activating the 
mitogen-activated protein kinase (MAPK) signaling pathways ERK1/2, p38 and JNK. α-SMA = alpha-
smooth muscle actin, PAI-1 = plasminogen activator inhibitor-1, TGF = transforming growth factor, 
TRK = tyrosine receptor kinase, SBE = Smad binding element, TF = transcription factor. 
 
The crucial role of TGF-β1 as a regulator of fibroblast differentiation has brought the focus 
on α-SMA induction and other fibrotic targets by TGF-β signaling. Extensive research 
revealed the important role of the TGF-β/Smad3 signaling pathway involved in the 
pathogenesis of fibrosis in many tissues. Transcription of α-SMA mediated by Smad3 is 
linked to the binding of Smad3 to the Smad binding element 1 which is upstream of the α-
SMA core promoter element (Hu et al., 2003, Uemura et al., 2005). Interestingly, Smad3 
null mice exhibit attenuated fibrosis in a wide range of experimental models (Bujak et al., 
2007, Dobaczewski et al., 2010). Indeed, a resistance was shown for bleomycin-induced 
pulmonary fibrosis or dermal fibrosis following irradiation (Zhao et al., 2002). However, α-






Smad3 is not solely responsible for myofibroblast differentiation (Schnabl et al., 2001). 
Although its key role in TGF-β1 mediated fibrosis is widely accepted, increasing evidence 
considers non-canonical signaling as an additional pivotal point (Biernacka et al., 2011). 
Indeed, it was shown that a TGF-β mediated fibrogenic program was initiated by the ERK 
pathway in SSc fibroblasts (Pannu et al., 2007). Another study highlighted the essential role 
of the p38 MAPK pathway in a model of renal fibrosis (Stambe et al., 2004). The relevance 
of both canonical and non-canonical TGF-β signaling regarding fibrosis, as well as potential 
interactions between pathways, remains poorly understood (Biernacka et al., 2011). 
Although TGF-β mediated myofibroblast activation is pivotal for a normally proceeding 
wound healing process, it should not be forgotten that persistent myofibroblasts activity 
seems to be responsible for abnormal scarring. Since myofibroblast activity is inseparable 
from TGF-β signaling, these signaling pathways are most likely involved in fibrotic 
conditions such as hypertrophic scars or keloids. 
Although many fundamental findings about myofibroblasts and their TGF-β mediated 
formation were accumulated in the past years, many aspects of abnormal scar growth and 
persistence are still questioned or unknown. This lack of knowledge contributes, indeed, to 
non-optimal or improvable treatment options for hypertrophic scars and keloids as 
described in 1st1st1st. Remarkably, one outstanding scar treatment emerged in recent 
years, which is the use of autologous fat grafting. Here, fat depots are harvested from body 
deposits and re-injected into scar tissue with promising outcome. This technique, and 







1.2. Multiple Functions of Adipose Tissue 
Adipose tissue is a complex organ that revealed surprising characteristics once it was 
studied in more detail. The traditional role, adipose tissue is attributed to, is energy storage. 
Often, adipose tissue is associated with obesity and is therefore connected with undesirable 
effects (Trayhurn and Beattie, 2001). However, what is many times not mentioned or known 
is the actual complexity of this tissue with its different subgroups of white, brown and 
beige/brite adipose tissue as well as its variety of cell types residing in this tissue, thereby 
enabling adipose tissue as an endocrine organ (Kershaw and Flier, 2004, Nedergaard et 
al., 2007). Indeed, fat mediates a plethora of beneficial effects to the human body including 
wound healing processes (Scherer, 2006). 
Adipose tissue is a special loose connective tissue composed of lipid-laden adipocytes. 
Those fat cells are held together by reticular fibers which are characterized by lobule 
formation and are usually found in a capillary and innervation network. Notably, adipocytes 
are not the sole cell type in adipose tissue even if they are the most prominent cell type by 
volume. But, in fact, adipocytes make up only up to 40% of the total cell mass of a fat pad 
with macrophages, fibroblasts, endothelial cells, mesenchymal stem cells, pericytes, blood 
cells and immune cells coming along (Rosen and Spiegelman, 2014). This multicellularity 
provides a first indication for the complex functions adipose tissue holds.  
When talking about the classical role of adipose tissue in the human body, it is usually the 
white adipose tissue (WAT) that is referred to. Contradictory to a classic organ localization, 
WAT distributes in single fat pads dispersed throughout the body. It is usually 
subcategorized into subcutaneous and internal depots. Subcutaneous fat layers are 
typically found beneath the skin in a region called hypodermis located between the dermis 
and the muscle. Internal depots are mainly composed of visceral fat that covers internal 
organs such as the heart or liver but also consist of non-visceral fat with intramuscular fat 
as an example (Rosen and Spiegelman, 2006). White adipocytes have a characteristic 
spherical form that vary greatly in size, ranging from 20 to 200 µm in diameter. Mature white 
fat cells contain a single large lipid droplet that takes about 90% of the cell volume (Rosen 
and Spiegelman, 2014). Interestingly, adipocytes possess the characteristic of changing 
their cell volume according to the current demand such as an increased lipid load. 
Therefore, a diameter increase up to 20-fold has been reported as well as a several 1000-
fold increased cell volume (Frühbeck, 2008). Described as unilocular, the lipid droplet is 
mainly made up by a mixture of triglycerides, neutral fats, phospholipids, fatty acids and 
glycerol (Rosen and Spiegelman, 2006). Notably, triglycerides in brown adipocytes are 
stored in multilocular fat droplets in contrast to white adipocytes with one large lipid vacuole. 






appearance. Recently, a third type of adipose tissue was discovered called beige or brite 
adipose tissue (Wu et al., 2012). Those adipocytes are found in white adipose tissue but 
show characteristics of brown adipocytes. An overview of the three different classes of 
adipocytes is shown in Fig. 5. 
 
Fig. 5: Morphology of the three different adipocyte types.  
Hematoxylin and eosin staining from (A) white adipocytes, (B) beige/brite adipocytes and (C) brown 
adipocytes. White adipocytes show a unilocular ft droplet whereas brown adipocytes exhibit multiple 
smaller ones and a high amount of mitochondria. Beige/brite adipocytes present an intermediate 
phenotype. (Keipert and Jastroch, 2014) 
 
As mentioned above, adipose tissue has been traditionally defined by its ability of energy 
storage. During times of high food intake and/or decreased energy expenditure, surplus 
energy is stored in white adipocytes in the form of neutral triglycerides. As soon as the food 
intake is limited or there is an increased need for energy expenditure, lipid reserves are 
released for energy generation. In order to achieve this, adipocytes contain lipases enabling 
cleavage of triglycerides into glycerol and free fatty acids (FFA) which are subsequently 
released and transported in the blood to the liver or muscle where they are used for fatty 
acid oxidation (Rosen and Spiegelman, 2006). Therefore, the main function of WAT is not 
only the energy storage in form of triglycerides but also the energy release in form of fatty 
acids. When 1994 leptin was discovered to be released by adipose tissue, another 
dimension was added to our knowledge of adipose tissue function (Zhang et al., 1994). By 
this, it was demonstrated that adipose tissue is capable of transmitting signals thereby 
regulating energy balance. Subsequent studies revealed even more cytokine-like factors 
released by adipocytes, therefore called adipokines, promoting the idea of adipose tissue 
as an endocrine organ (Trayhurn and Beattie, 2001). Leptin is a hormone that is widely 
seen as the most important factor secreted by WAT and its functions have been extensively 
investigated. Leptin seems to interact with a variety of neuroendocrine systems leading to 
the inhibition of food intake or affecting energy expenditure (Trayhurn and Beattie, 2001). 
Moreover, leptin is involved in signaling toward the reproductive system, as well as the 
immune system and in angiogenesis (Friedman and Halaas, 1998). In addition, inhibition of 






reported, demonstrating the major impact of leptin in metabolic processes (Trayhurn and 
Beattie, 2001). Interestingly, leptin exerts most of its effects through hypothalamic 
pathways, especially in connection with energy intake and expenditure. Therefore, leptin 
receptors, members of the cytokine class I receptor superfamily, are found in both the 
central nervous system as well as the periphery (Bjorbæk and Kahn, 2004). Besides leptin, 
adiponectin is a well known adipokine mediating the effects of WAT. Adiponectin belongs, 
together with leptin, to the insulin-sensitizing adipokines. Both proteins can induce insulin-
stimulated lipogenesis thereby facilitating triglyceride accumulation and adipose 
expandability (Sethi and Vidal-Puig, 2007). Despite leptin and adiponectin, there are a 
variety of additional proteins involved in lipid and lipoprotein metabolism in WAT. These 
include the lipoprotein lipase, apolipoprotein lipase E and perilipin as well as retinol binding 
protein or fatty acid binding protein 4 (FABP4) (Kershaw and Flier, 2004). On top of the 
already mentioned adipokines secreted by white adipocytes, there is a plethora of other 
secreted factors with an amount ranging from 200 to 300 proteins (Ojima et al., 2016). 
Nonetheless, it needs to be emphasized that fatty acids are the major secretory product of 
WAT representing their main function as fuel reserve.  
In contrast to WAT, brown adipose tissue (BAT) exerts further functions. Brown adipocytes 
are specialised in thermogenesis; thus, they can produce heat through transferring energy 
from food by mitochondrial "uncoupling" of oxidative phosphorylation of FFA. Here, the 
uncoupling protein-1 (UCP-1) plays a major role which is uniquely expressed in brown 
adipocytes. UCP-1 breaks up the proton gradient which is usually established by the 
electron transport chain at the inner membrane of mitochondria. Subsequently, heat is 
generated by energy expense in form of ATP (Cannon and Nedergaard, 2004).  In 
newborns, BAT depots are found in specific body regions such as the neck or the 
interscapular region ensuring an adequate body temperature. Usually, the amount of BAT 
decreases with age since there are other mechanisms keeping the body warm (Cousin et 
al., 1992). The third type of adipose tissue was discovered called beige or brite adipose 
tissue. Those adipocytes are found in white adipose tissue but show characteristics of 
brown adipocytes, particularly UCP-1 expression. Speculations about the protective 
mechanisms of WAT browning against obesity has led to an increased research interest in 
this area (Lo and Sun, 2013). 
In recent years, adipose tissue did not only attracted attention because of its multiple 
functions in the human body, especially regarding scar regeneration, but also because of 







1st2nd1st Adipose-derived Stem Cells (ASCs) 
The term “stem cell” was first used 1868, but it was more commonly applied with our current 
understanding of a stem cell at the beginning of the 20th century with the discovery of a 
putative common progenitor for the hematopoietic system (Ramalho-Santos and 
Willenbring, 2007). Confirmation of the existence of a hematopoietic stem cell (HSC) was 
achieved in the 1960s alongside with an extensive characterization of cell surface markers 
(Becker et al., 1963, Weissman, 2000). Most striking is their capability of self-renewal and 
multilineage differentiation, two characteristics that are now seen as relevant for a true stem 
cell (Bianco and Robey, 2001). In addition to HSCs, the existence of non-hematopoietic 
progenitor cells in bone marrow was verified with those cells showing at least some capacity 
of self-renewal as well as differentiation potential into mesenchymal cells such as 
osteocytes, chondrocytes and adipocytes (Friedenstein et al., 1987, Prockop, 1997). 
Therefore, those progenitor cells were termed as mesenchymal stem cells (MSCs) or bone 
marrow-derived MSCs (Prockop, 1997). With these observations, growing interest for the 
field of MSC-based therapies came up: bone marrow-derived MSCs were investigated for 
their potential in treating diseases such as osteogenesis imperfecta, strokes or myocardial 
infarctions with some promising therapeutic outcome (Picinich et al., 2007). However, the 
use of bone marrow-derived MSCs has raised some issues since harvesting of those MSCs 
is related with pain, side effects and morbidity (Ankrum and Karp, 2010). Therefore, 
alternative sources for MSCs were being sought with the discovery of certain tissues such 
as the dental pulp, Wharton jelly, amniotic fluid and indeed adipose tissue (Zuk et al., 2002, 
da Silva Meirelles et al., 2006). 
Especially the discovery of MSCs in adipose tissue, the so-called adipose-derived stem 
cells (ASCs) led to an explosion in research focusing on ASCs since accessibility and 
harvesting of those MSCs shows distinct advantages over the original source of bone 
marrow (Gimble et al., 2007, Zuk et al., 2001). Adipose tissue is easily available in sufficient 
amounts because of the high abundance of fat in the human body as well as it is often 
considered as surgical waste in plastic surgery. In addition, adipose tissue obtained by 
liposuction or excision is associated with little pain and accepted as a safe procedure 
(Fraser et al., 2006). Moreover, the ASC isolation process can be handled fast and simple 
with an enormous yield of approximately 2 × 105 cells per gram adipose tissue (Hass et al., 
2011). The isolation procedure is based on an enzymatic digestion involving collagenase 
type I, resulting in the so-called stromal vascular fraction (SVF). The SVF is a highly 
heterogeneous cell population including ASCs but also endothelial progenitor cells, 
pericytes or macrophages. ASCs can be selected from the SVF by their ability of plastic 






characterization of ASCs in vitro is their cell surface protein profile. Several different marker 
profiles are being considered as relevant to specifically identify ASCs facing tremendous 
variations between studies as the surface expression changes as a function of time in 
passage and plastic adherence (Cawthorn et al., 2012). However, distinct expression 
patterns were repeatedly shown in various studies, such as CD34+, CD105+ and CD45- 
(Dominici et al., 2006). In addition, ASCs are typically verified by their trilineage 
differentiation potential into osteocytes, chondrocytes and adipocytes (Zuk et al., 2001). 
Although the discovery of ASCs in adipose tissue itself is fascinating, the presumption that 
ASCs could influence fibrotic processes gathered even more attention in the field of 
regenerative medicine (Schaffler and Buchler, 2007). Indeed, several in vitro and in vivo 
studies reported on regenerative effects of ASCs. For instance, injection of ASCs into a 
rabbit ear model reduced scarring (Zhang et al., 2015). Another study reported on enhanced 
wound healing in a diabetic nude mice model with ischemic wounds (Kim et al., 2011). 
Interestingly, an in vitro study demonstrated beneficial effects of ASCs on wound healing in 
fibroblasts via secretory factors (Kim et al., 2007). Although many promising cell-based and 
animal studies exist that report on positive effects of ASCs, however, well-designed 
randomized placebo-controlled clinical trials are still missing (van Dongen et al., 2018). This 
is aggravated by the fact that ASC administration provides many variations, with options 
that ASCs being cultivated before injection, the usage of the whole SVF or lipografts such 
as fragmented adipose tissue being transferred. To date, two clinical trials studied for 
instance the injection of cultured ASCs into patients with non-healing ischemic ulcers (Bura 
et al., 2014, Lee et al., 2012). After 6 months, 66.7% of patients showed indeed a positive 
response rate to ulcer healing (Lee et al., 2012). Even if the data obtained so far are 
promising, however, the mode of action of ASCs in these reports is still unclear and so is 
the question if ASCs are the only cell type promoting regenerative processes or if other 
cellular components of the adipose tissue, such as adipocytes, might play a role as well. 
1.2.2. Adipogenesis: from ASCs to Adipocytes 
The differentiation of ASCs into adipocytes is a complex, multi-step process involving 
various transcriptional events. Adipogenesis is widely seen as a two-phase procedure with 
the first phase being described as the determination phase. Here, ASCs are committed to 
the adipocyte lineage resulting into the conversion of preadipocytes. Preadipocytes are 
phenotypically not distinguishable from ASCs but lost their potential to differentiate into 
other cell lineages (Cawthorn et al., 2012). In the second, terminal phase, preadipocytes 
acquire characteristic adipocyte features presenting a lipid-laden mature adipocyte at the 
end of this process (Farmer, 2006). Interestingly, the terminal phase of adipogenesis is 






established cell line models such as the mouse lines 3T3-L1 and C3H10T1/2 or human 
preadipocytes, which are all already committed to the adipocyte lineage (Rosen et al., 
2002). 
Overall, adipogenesis is regulated by a comprehensive network of transcriptional activators 
leading to the expression of hundreds of proteins involved in establishing the mature 
adipocyte phenotype. At the centre of this network, there are two groups of transcription 
factors monitoring the differentiation process: peroxisome proliferator-activated receptor 
gamma (PPARɣ) and CCAAT/enhancer-binding proteins (C/EBPs) (Fig. 6). PPARɣ, in 
particular, is considered as the master regulator of adipogenesis with being both necessary 
and sufficient for differentiation (Rosen et al., 1999).  
 
  
Fig. 6: Schematic overview of adipogenesis with a focus on the differentiation of 
preadipocytes into adipocytes.  
After adipose-derived stem cell (ASC) commitment to preadipocytes, a complex differentiation 
process into adipocytes is initiated. The two central transcription factors are peroxisome proliferator-
activated receptor (PPAR)ɣ and CCAAT/enhancer-binding protein CEBPα which are activated by 
various factors such as CEBPβ, CEBPδ, Krüppel-like factors (KLFs) and Sterol regulatory element-







Indeed, forced PPARɣ expression is sufficient for adipocyte formation and no factor has 
been discovered so far that promotes adipogenesis in the absence of PPARɣ (Rosen et al., 
1999). In concordance with these findings, almost all pro-adipogenic factors seem to 
function by activating PPARɣ. Furthermore, important signaling pathways in adipogenesis 
converge on the level of increased PPARɣ expression or activity. PPARɣ belongs to a 
nuclear receptor superfamily and must therefore heterodimerize with another nuclear 
hormone receptor (the retinoid X receptor, RXR) in order to bind DNA and induce the 
transcription of target genes (Tontonoz et al., 1994a). Interestingly, PPARɣ is expressed in 
two isoforms, due to alternative splicing, with PPARɣ1 being expressed in almost all tissues 
whereas PPARɣ2 is almost exclusively found in adipose tissue (Rosen et al., 1999). Studies 
demonstrated that both isoforms can induce adipogenesis but PPARɣ2 plays a major role 
in insulin sensitivity since PPARɣ2 deficient mice were shown to be insulin resistant (Kubota 
et al., 1999). PPARɣ has been linked to the induction of FABP4 as well as other adipocyte-
specific genes such as adiponectin or perilipin. As for all nuclear receptors, PPARɣ is a 
ligand-activated transcription factor. A wide variety of natural endogenous ligands and 
synthetic agonists exists such as thiazolidinediones (TZDs), synthetic agents commonly 
used in anti-diabetic therapies. Endogenous ligands for PPARɣ include eicosanoids, as for 
instance the prostanoid 15-deoxy-Δ12,14-prostaglandin-J2 (15dPGJ2) or arachidonic acid 
derivates such as 15-hydroxy-eicosatetraenoic acid (15-HETE) (Lecka-Czernik et al., 
2002). Also, natural fatty acids like linoleic acid, eicosapentaenoic acids, nitrolinoleic acid 
and LPA belong to known PPARɣ ligands (Tontonoz et al., 1994b). 
The other important group of transcription factors, C/EBPs, belong to the basic leucin-zipper 
class of transcription factors with six different isoforms that have been described, all of which 
need homo- or heterodimerization with a leucin zipper domain for activation (Darlington et 
al., 1998). Several factors are known to interplay with C/EBP regulation, for example cyclic 
adenosine monophosphate (cAMP), a well-known inducer of adipogenesis mediating 
increased expression of C/EBPα and β. Various gain- and loss-of-function studies revealed 
the crucial role of this group of transcription factors during adipogenesis (Wu et al., 1999). 
Especially C/EBPα came into the focus of researchers since ectopic expression of C/EBPα 
was demonstrated to trigger fat cell formation in fibroblastic cells (Freytag et al., 1994), 
whereas C/EBPα knockout mice died quickly after birth due to their inability to produce 
glucose (Wang et al., 1995). Interestingly, C/EBPα can not induce adipogenesis in the 
absence of PPARɣ while PPARɣ was shown to drive the adipogenic program in C/EBPα-
deficient mouse embryonic fibroblasts (Rosen et al., 2002). These observations 
demonstrate the determinant role of both PPARɣ and C/EBPα, though PPARɣ seems to be 






further studied and it is now established that there is a cascade of transcription factors 
leading to their expression. Here, two other members of the C/EBP family have an impact, 
C/EBPβ and δ. In more detail, C/EBPβ and δ seem to be expressed earlier in adipogenesis 
than C/EBPα, as shown by the group of McKnight. They demonstrated C/EBPα induction 
by ectopic expression of C/EBPβ and δ in 3T3-L1 preadipocytes (Cao et al., 1991, Yeh et 
al., 1995).  Here, however, a link to PPARɣ induction was not investigated but a high number 
of other studies revealed the involvement of C/EBPs in PPARɣ production (Wu et al., 1995, 
Wu et al., 1996, Christy et al., 1991, Clarke et al., 1997). These days, it is widely accepted 
that C/EBPβ and ɣ induce PPARɣ expression which leads to C/EBPα production (Lin and 
Lane, 1994, Tontonoz et al., 1994b). Nonetheless, adipogenic differentiation does not only 
depend on C/EBPs and PPARγ but is a complex network of different factors, as depicted in 
Fig. 6. In addition to C/EBPs and PPARγ other factors such as SREBP1c or the Krüppel-
like family (KLFs) are vital for adipogenic differentiation (Oishi et al., 2008, Li et al., 2005, 
Kim and Spiegelman, 1996). 
Although the transcriptional control of adipogenesis is extremely well characterized, less is 
known about ASCs and their preadipocyte commitment. One outstanding factor influencing 
adipocyte commitment is the zinc-finger protein 423 (Zfp423), as shown by Gupta and 
coworkers (Gupta et al., 2010). They reported an increased expression of PPARɣ in non-
adipogenic NIH-3T3 fibroblasts after ectopic expression of Zfp423. Interestingly, they linked 
Zfp423-induced PPARɣ expression to the activity of bone morphogenetic proteins (BMPs), 
members of the TGF-β superfamily. Indeed, BMPs have been considered as pro-
adipogenic factors before, especially BMP-2 and -4. BMP-4 treatment, for instance, led to 
an augmented PPARɣ expression in C3H10T1/2 cells and enhanced their adipogenesis, 
subsequently (Tang et al., 2004). As shown in Fig. 7, BMP-2 and BMP-4, as well as other 
members of the BMP family, exert their function through binding to hetero-oligomeric 
receptor complexes consisting of BMP type I (BMPR1) and type II (BMPR2) receptors 
leading to phosphorylation and thus, activation of Smad1, 5 and 8 (Heldin et al., 1997). For 
BMP-2, binding of the Smad1/4 complex to the PPARγ2 promotor upon BMP-2 stimulation 
was shown (Sottile and Seuwen, 2000). How Smads exert these effects remains elusive. 
Remarkably, Zfp423 contains a Smad binding site and is considered as a Smad coactivator 
thereby mediating the proadipogenic impact of BMPs (Hata et al., 2000). Notably, another 
zinc-finger protein, Schnurri-2, also directly binds to Smad1/4 following BMP-2 stimulation, 
ultimately inducing PPARɣ expression (Jin et al., 2006). Despite BMP-2 and -4, BMP-7 is a 
known pro-adipogenic factor of the BMP family, although related to brown adipogenesis, 
since an increased UCP-1 expression was observed in C3H10T1/2 cells following BMP-7 






Even though the interest for a better understanding of adipogenesis is growing, there are 
even more efforts undertaken in finding anti-adipogenic factors due to increasing health 
issues originating from obesity. For instance, Wnt (wingless/integrated) signaling is known 
as a molecular switch, that, when activated, represses adipogenesis (Ross et al., 2000). 
This was shown especially by the group of MacDonald who performed an overexpression 
of Wnt1 in 3T3-L1 preadipocytes showing to inhibit adipogenesis (Ross et al., 2000, Bennett 
et al., 2002). This inhibition was linked to a blocked induction of both PPARγ and C/EBPα. 
 
 
Fig. 7: Commitment to the adipocyte lineage.  
The commitment of adipose-derived stem cells (ASCs) to the adipocyte lineage is so far not 
completely understood. Bone morphogenetic proteins (BMPs) are known pro-adipogenic factors that 
exert their signals through BMP receptor complexes thereby activating Smad 1/5/9 leading to 
peroxisome proliferator-activated receptor (PPAR)ɣ induction. In contrast to that, transforming 
growth factor (TGF)-β as well as Wnt signaling are known pathways inhibiting PPARɣ-mediated 
adipogenesis. 
 
In the context of anti-adipogenic influences, again, also TGF-β signaling must be 
mentioned, playing a key part (Choy and Derynck, 2003). Considering the complexity of the 
adipogenic developmental system, it is somewhat not surprising that TGF-β superfamily 






part in adipogenesis but also the TGF-β/Activin family. In 3T3-L1 cells for instance, TGF-β 
treatment inhibited adipogenic conversion (Ignotz and Massague, 1985). After first 
indications of an interplay between TGF-β and PPARγ, further studies were conducted 
addressing this relationship. One interesting study dealing with skin biopsies of SSc 
patients, an autoimmune disease of the connective tissue associated with high levels of 
TGF-β, demonstrated a reduced PPARγ expression (Wei et al., 2010). Further insights 
revealed an inverse correlation between pronounced TGF-β activity, for instance by the 
high mRNA expression of the TGF-β target PAI-1, and impaired PPARγ-regulated gene 
signature, thereby indicating a reciprocally antagonistic relationship between PPARγ and 
TGF-β signaling in fibrosis (Wei et al., 2010). Therefore, the counteracting factors of TGF-
β signaling as one of the main fibrotic elements and PPARγ, the master regulator of 
adipogenesis, give first indications for a correlation between fibrotic scar tissue and anti-
fibrotic adipose tissue. Interestingly, the application of fat injections into wound areas and 
fibrotic lesions revealed promising results with regard to tissue regeneration and scar 
appearance. Further insights into the underlying mechanism of the observed changes 
following fat grafting could also provide new concepts for the relationship between PPARɣ 
and TGF-β. 
1.2.3. Autologous Fat Grafting 
Historically, the use of fat transfer can be traced back to the year 1793 with the work of 
Neubert who first harvested fat from a patient’s arm to fill a soft tissue defect in his cheek 
caused by tuberculosis (Billings and May, 1989). Over the years, more and more reports 
about autologous fat grafting came up but often included negative observations due to fat 
reabsorption. It was not until the work of Coleman, whose procedure is still referred to as 
the gold standard for fat grafting, that results became more reliable (Coleman, 1995). The 
Coleman technique is based on an initial lipoaspiration step followed by centrifugation of 
the fatty tissue and its reinjection. Although this technique is still considered as the standard 
procedure, it has undergone several modifications to improve adipocyte survival. Generally, 
there are plenty of possible ways for autologous fat grafting because of minor or rather 
major variations of Coleman’s work. Depending on the surgeon’s experience and 
preferences, fat collection can be performed by vacuum aspiration, syringe aspiration or 
surgical excision (Bellini et al., 2017). Also, fat processing prior to re-injection can comprise 
some modifications. Fat processing is necessary since the lipoaspirate consists not only of 
adipocytes but contains collagen fibers, blood and debris which could cause inflammation 
at the recipient’s site. Therefore, the tissue is often sedimented, washed and centrifuged for 
graft preparation (Cleveland et al., 2015). In addition, there is no consensus on the best 






being used for optimal cell viability (Kakagia and Pallua, 2014). Besides all these technical 
variations, less deliberations are queried for potential applications of fat grafts. One field 
where autologous fat grafting has been widely used is reconstructive breast surgery. Here, 
lipofilling can be used for restoring the breast profile after mastectomy, for example. In most 
cases, lipofilling is combined with the usage of implants or muscle flaps with or without 
tissue expansion (Simonacci et al., 2017). However, one major difficulty plastic surgeons 
are still facing is the possibility for graft re-absorption with reports of 50-90% graft loss 
(Tremolada et al., 2010). Therefore, repeated lipotransfers are preferred for maximum take. 
In addition to reconstructive surgery, another important field of fat graft application is 
aesthetical surgery, mainly focussing on facial or hand rejuvenation since adipose tissue 
holds excellent filling properties (Rohrich and Pessa, 2007, Hoang et al., 2016). 
Even more importantly, and as mentioned before, autologous fat grafting can be used for 
scar treatment, thus representing now one of the most favorable usages of adipose tissue 
in plastic surgery (Negenborn et al., 2016). In fact, fat transplantation can be used not only 
to fill atrophic scars but also to reduce scar contractures as a regenerative alternative to 
other surgical techniques. One of the first reports on the regenerative potential of fat grafting 
was presented by Rigotti et al., who showed improvements on human skin after treating 
radiation-induced skin lesions with fat injections (Rigotti et al., 2007) More promising studies 
emerged on the use of fat for scar treatment. For instance, a case series of three patients 
demonstrated significant improvement in burn scars following fat transplantation in 2008 
(Klinger et al., 2008). Although more studies with intriguing outcomes on scar improvement 
appeared, most studies were small prospective or retrospective cohort and case studies 
leaving a demand for randomized, blinded and placebo-controlled studies. A more 
comprehensive study of Klinger and colleagues indeed demonstrated significant 







Fig. 8: Beneficial effects of autologous fat grafting. 
Left: A hypertrophic scar covers a patient’s leg thereby affecting its movement. Right: After 
autologous fat grafting, the treated tissue appears softer and less coloured. Also a reduction in scar 
hypertrophy is visible allowing for better leg movement. (Klinger et al., 2013) 
 
  
In this study, 694 patients with painful and retractile scars were subjected to autologous fat 
grafting, where fat was injected according to the Coleman technique (Klinger et al., 2013). 
Notably, included scars derived from burn injuries, road trauma, domestic accidents or 
various surgery procedures. As a result, pain relief and an increased elasticity of the scarred 
area was reported in all patients after fat injection. These effects were already observed 
after 14 days and were constant after 1-year follow-up. Another important observation was 
a regain of mobility in the treated areas such as joints, eyelids or nasal valve. In addition, 
histological improvements were observed with new collagen deposition, local 
hypervascularity and dermal hyperplasia. More generally speaking, treated areas regained 
characteristics similar to normal skin or in other words, scars became less different from 
normal skin and less visible. 
The exact mechanism by which autologous fat grafting improves scar tissue remains 
unclear (Fredman et al., 2017), even if there is a wide range of speculations implicating 
paracrine effects by one or more cellular components of adipose tissue (Kim et al., 2007, 
Spiekman et al., 2014). For a better understanding of the mode of action of autologous fat 







1.3. Aim of this thesis 
About 100 million patients each year are affected by abnormal scarring after surgery (Sund 
and Arrow, 2000). Patients dealing with hypertrophic scars or keloids suffer from severe 
long-term functional and psychological issues. Therefore, there is an unmet clinical need 
for an effective, targeted therapy and prevention, which would be based on an action or a 
modulation of a particular factor with clarified mechanism of action that has a beneficial 
effect on those fibrotic conditions (Hoerst et al., 2019). Notably, the injection of adipose 
tissue into scarred areas reveals promising results with improved scar characteristics, 
however, little is known about the underlying mechanisms and cell types involved. 
Therefore, this thesis aims to unravel the crosstalk between cells of adipose tissue and 
connective tissue. There are several interesting points this study would like to draw attention 
to: on the hand, clarification would be necessary in relation to the mode of action of adipose 
tissue. Here, inter alia, the cellular component being responsible for the observed 
regenerative effect upon fat grafting needs to be identified. So far, mainly ASCs were 
studied for their regenerative potential, but adipocytes with their diverse characteristics 
would present promising candidates as well. Moreover, the actual mediator being released 
or transmitted from adipose tissue cells needs to be determined. On the other hand, further 
studies on the observed changes scar tissue undergoes following fat injection are required. 
What happens to the myofibroblast in this fibrotic tissue? Although it was always believed 
that myofibroblasts undergo apoptosis after tissue repair, increasing evidence suggests 
alternative ways for myofibroblasts disappearance, such as re- or trans-differentiation 
processes. Which intracellular pathways and molecular switches are involved in this 
regeneration? Those complex and crucial points will be addressed by establishing a co-
cultivation between ASCs or adipocytes on the one hand and myofibroblasts or hypertrophic 
scar fibroblasts on the other hand. Since myofibroblasts’ fate following fat grafts is of great 
interest in this study, myofibroblasts will be analyzed for their characteristic attributes as 
well as for intracellular changes with the TGF-β network being in the focus. 
Answers or even promising indications to the raised questions could help to develop 
strategies to specifically and ultimately inhibit myofibroblast formation. Altogether, deeper 
insights about the cellular crosstalk between adipose and connective tissue may contribute 
to improved treatment options for abnormal scars as well as their prevention. In addition, 
with a better understanding of skin scarring further insights into the (patho-)physiological 




MATERIALS AND METHODS 
 
2.1.  Materials 
2.1.1.  Reagents 
β-glycerophosphate 
Acrylamide 
Sigma-Aldrich, Munich, DE 
Sigma-Aldrich, Munich, DE 
Alcian Blue Sigma-Aldrich, Munich, DE 
Alizarin Red S 
Ammonium persulfate (APS) 
Sigma-Aldrich, Munich, DE 
Sigma-Aldrich, Munich, DE 
Ascorbate-2-phosphate Sigma-Aldrich, Munich, DE 
Bone Morphogenetic Protein (BMP)-4 Miltenyi Biotec, Bergisch-Gladbach, DE 
Bovine Serum Albumin (BSA) Carl Roth, Karlsruhe, DE 
Collagenase I Worthington, Lakewood, NJ, US 
DAPI Mounting Medium Dianova Hamburg, DE 
Dexamethasone 
Dispase II 
Sigma-Aldrich, Munich, DE 
Roche Diagnostics, Mannheim, DE 
Dithiothreitol (DTT) Sigma-Aldrich, Munich, DE 







Sigma-Aldrich, Munich, DE 
Carl Roth, Karlsruhe, DE 
Carl Roth, Karlsruhe, DE 
Merck, Darmstadt, DE 
Erkel AHK, Berlin, DE 
Dianova, Hamburg, DE 
GW9662 
Hank’s Buffered Salt Solution 
Hematoxylin 
Sigma-Aldrich, Munich, DE 
Life Technologies, Darmstadt, DE 
Carl Roth, Karlsruhe, DE 
Fetal Bovine Serum Biochrom, Berlin, DE 
IBMX Life Technologies, Darmstadt, DE 
Insulin Roche, Grenzach-Wühlen, DE 
LDN-193189 Sigma-Aldrich, Munich, DE 
L-Glutamine Sigma-Aldrich, Munich, DE 
Oil-Red-O Sigma-Aldrich, Munich, DE 
Penicillin/Streptomycin Sigma-Aldrich, Munich, DE 
Phosphate Buffered Saline (PBS) Sigma-Aldrich, Munich, DE 
Protease/Phosphatase Inhibitor Cocktail Cell Signaling, Massachusetts, US 





Roti®-Histofix Carl Roth, Karlsruhe, DE 
Roti®-Histokit Carl Roth, Karlsruhe, DE 
Roti®-Histol 
Sodium chloride (NaCl) 
Sodium hydroxide (NaOH) 
TEMED 
Carl Roth, Karlsruhe, DE 
Carl Roth, Karlsruhe, DE 
Sigma-Aldrich, Munich, DE 
Carl Roth, Karlsruhe, DE 
Tissue Freezing Medium Leica Biosystems, Nussloch, DE 
Transforming Growth Factor-Beta1 (TGF-β1) 
Tris 
Miltenyi Biotec, Bergisch-Gladbach, DE 
Carl Roth, Karlsruhe, DE 
Trypsin/EDTA Sigma-Aldrich, Munich, DE 
Tween-20 Carl Roth, Karlsruhe, DE 
 
 
2.1.2.  Cell Culture Media 
Fibroblast Basal Medium (FBM) DMEM supplemented with: 
1 % penicillin/streptomycin 
1 % L-glutamine 
Fibroblast Growth Medium (FGM) FBM supplemented with: 
7.5 % FBS 
ASC Growth Medium DMEM/F12 supplemented with: 
10 % FBS 
1 % penicillin/streptomcyin 
Adipocyte Differentiation Medium ASC Growth Medium supplemented 
with: 
1 µM dexamethasone 
0.5 mM IBMX 
10 µg/mL insulin 
 
2.1.3.  Kits 
Pierce® BCA Protein Assay Kit Thermo Fisher Scientific, Schwerte, DE 
SignalFire™ ECL reagent Cell Signaling, Frankfurt/Main, DE 
NE-PER Nuclear and Cytoplasmic Extraction Thermo Fisher Scientific, Schwerte, DE 
BMP 2,4,6,7 Elisa Kit Thermo Fisher Scientific, Schwerte, DE 
InnuPREP RNA Mini Kit Analytik Jena, Jena, DE 
iScript cDNA Kit  Bio-Rad, Munich, DE 




iTaq™ Universal SYBR® Green Supermix Kit Bio-Rad, Munich, DE 
Cell proliferation Elisa, BrdU Kit 
Glycerol-3-Phosphate Dehydrogenase 
(G3PDH) Assay Kit 
Roche, Basel, Switzerland 
Abcam, Cambridge, UK 
 
2.1.4.  Antibodies 
Rabbit anti-β-Tubulin CST, Massachusetts, US 1:1000 in 5% (w/v) milk  




1:1000 in 5% (w/v) milk  
Mouse anti-β-Actin Abcam, Cambridge, UK 1:10.000 in 5% (w/v) milk  
Rabbit anti-Collagen I Abcam, Cambridge, UK 1:1000 in 5% (w/v) milk  
Rabbit anti-Collagen III Abcam, Cambridge, UK 1:1000 in 5% (w/v) milk  
Rabbit anti-PPARɣ CST, Massachusetts, US 1:1000 in 5% (w/v) milk  
Rabbit anti-Histone H3 CST, Massachusetts, US 1:1000 in 5% (w/v) milk  
Rabbit anti-GAPDH CST, Massachusetts, US 1:1000 in 5% (w/v) milk  
Rabbit anti-Phospho-p42/44 
MAPK (Erk1/2) 
CST, Massachusetts, US 1:1000 in 5% (w/v) BSA  
Rabbit anti-p44/42 MAPK 
(Erk1/2) 
CST, Massachusetts, US 1:1000 in 5% (w/v) BSA  
Rabbit anti-Phospho-
SAPK/JNK 
CST, Massachusetts, US 1:1000 in 5% (w/v) BSA  
Rabbit anti-SAPK/JNK CST, Massachusetts, US 1:1000 in 5% (w/v) BSA  
Rabbit anti-Smad 2/3 CST, Massachusetts, US 1:1000 in 5% (w/v) BSA  
Rabbit anti-Phospho-
Smad2/Smad3 
CST, Massachusetts, US 1:1000 in 5% (w/v) BSA  
Rabbit anti-Phospho-
Smad1/Smad5/Smad 9 
CST, Massachusetts, US 1:1000 in 5% (w/v) BSA  
Anti-Rabbit IgG, HRP-linked CST, Massachusetts, US 1:10.000 in 5% (w/v) milk  
Anti-Mouse IgG, HRP-linked CST, Massachusetts, US 1:10.000 in 5% (w/v) milk  
PE anti-human CD34 BioLegend, California, 
US 
5 µl/106 cells  
FITC anti-human CD105 Miltenyi Biotec, Bergisch-
Gladbach, DE 
5 µl/106 cells  
PE anti-human CD45 Miltenyi Biotec, Bergisch-
Gladbach, DE 





5 µl/106 cells 
 
 





IgG Alexa Fluor®488 
IgG Alexa Fluor®594 
Abcam, Cambridge, UK 
Abcam, Cambridge, UK 
1:400 in PBS 
1:400 in PBS 
 
2.1.5.  Primer 
Adiponectin 5’ AGGGTGAGAAAGGAGATCC  
5’ GGCATGTTGGGGATAGTAA 




Collagen 1 (Col1) 
 
Collagen 3 (Col3) 
 
Fibronectin 





5’ GTGTGTTTCGTGCAACCATC    
5’ GGTGACACTTATGAGCGTCCTAAA 
5’ AACATGTAACCACCAGTCTCATGTG 
Id1 5’ CTGCTCTACGACATGAACGGC  
5’ TGACGTGCTGGAGAATCTCCA  
Leptin 5’ TGCATTCCCAGTGGTCAAAC  
5’ TGCATTTGGCTGTTCAGCTG 
PPARγ 5’ ATGGAGTTCATGCTTGTGAAGGA      
5’ TGCAAGGCATTTCTGAAACCG 
ZNF423 5‘ CCAAATCCACGTTGCCAACCA  
5‘ TGCTCAATGAGGTGACAGAGGAG 
GAPDH 5’ CTCTCTGCTCCTCCTGTTCGAC  
5’ TGAGCGATGTGGCTCGGCT 
 
2.1.6.  Software 
ImageJ, Version 1.46r National Institute of Health, MD, US 
GraphPad Prism 
STRING database, Version 11.0 
GraphPad Software, La Jolla, CA, US 
https://string-db.org/ 
WinMDI software, Version 2.8 Scripps Institute, La Jolla, CA, US 
 
2.1.7.  Consumables 
Blotting Pads VWR, Pennsylvania, US 
Cell Culture Inserts Falcon®, 3 µm pore size Corning, Amsterdam, NL 
Cell Culture flasks (75 cm², 150 cm²) 
Cell culture plates (10 cm) 
TPP, Melbourn, UK 
TPP, Melbourn, UK 
Cell strainer (70 + 100 µm) Sigma-Aldrich, Munich, DE 
Centrifuge tubes (15, 50 mL) Sarstedt, Nürnbrecht, DE 
Cover slips Gerhard Menzel, Braunschweig, DE 
Embedding molds 
Forceps 
Sigma-Aldrich, Munich, DE 
Carl Roth, Karlsruhe, DE 




Hard-Shell 480 PCR Plates  Bio-Rad, Munich, DE 
Multiwell cell culture plates (6, 12, 96-well) VWR, Pennsylvania, US 
Nitrocellulose membrane 
Nitril gloves 
Bio-Rad, Munich, DE 
Hansa-Trading HTH, Hamburg, DE 
Parafilm 
PCR grade tubes 
PCR stripes 
Carl Roth, Karlsruhe, DE 
Sarstedt, Nürnbrecht, DE 
Carl Roth, Karlsruhe, DE 
Pipette tips (10, 100, 1000 µL) Sarstedt, Nürnbrecht, DE 
Pipette tips with filter (10, 100, 1000 µL) Sarstedt, Nürnbrecht, DE 
Polylysine slides 
Scalpels 
Gerhard Menzel, Braunschweig, DE 
Carl Roth, Karlsruhe, DE 
Serological pipettes (5, 10, 25 mL) 
Syringes 
Sarstedt, Nürnbrecht, DE 
Carl Roth, Karlsruhe, DE 
Syringe filters (0.45 µm) Sarstedt, Nürnbrecht, DE 
 
2.1.8.  Devices 
Autoclave V Series 
Balance XS205 dualRange 
Centrifuge, Eppendorf Centrifuge 5415 C 
Centrifuge, Megafuge 1.0 R 
CO2 Incubator 
CO2-free Incubator 
Cryotome Leica CM1510 S 
Systec, Wettenberg, DE 
Mettler-Toledo, Giessen, DE 
Eppendorf AG, Hamburg, DE 
Heraeus, Hanau, DE 
Heraeus, Hanau, DE 
Heraeus, Hanau, DE 
Leica Biosystems, Nussloch, DE 
Digital camera, EOS 1000D Canon 
FACSCalibur BD Biosciences, San Jose, CA, US 
Fluorescence microscope BZ-8000 Keyence, Neu-Isenburg, DE 
FLUOstar Optima 
LaminAir HB 2472 
BMG Labtech, Ortenberg, DE 
Heraeus, Hanau, DE 
LightCycler 480 
Microscope, phase contrast Axiovert 135 
Roche, Mannheim, DE 
Carl Zeiss, Jena, DE 
Mini-PROTEAN Tetra System  
Mr. Frosty 
Neubauer cell counting chamber 
Bio-Rad, Munich, DE  
Thermo Fisher Scientific, Waltham, UK 
Carl Zeiss, Jena, DE 
PCR thermo cycler, Tgradient  
pH meter 766 
Pipettes (10, 100, 1000 µl) 
Biometra, Jena, DE  
Knick, Berlin, DE 
Eppendorf, Hamburg, DE 
PXi/PXi Touch gel imaging system  Syngene, Cambridge, UK 





Trans-Blot Turbo Blotting System BioRad, Munich, DE 




2.2.  Methods 
2.2.1.  Cell Culture 
2.2.1.1. Dermal Fibroblast Isolation & Differentiation 
Primary human fibroblasts were isolated from juvenile foreskin following circumcision 
(approved by the ethics committee of the Charité–Universitätsmedizin Berlin, Germany, 
EA1/081/13). Therefore, juvenile foreskins were washed in PBS, minced into 3 cm thick 
pieces and placed in a dispase solution (1,2 U/ml dispase in PBS) overnight at 4 °C. The 
next day, the epidermis was separated from the dermis by using forceps. Subsequently, the 
dermis pieces were placed in a 6-well cell culture plate and cultivated in Dulbecco’s modified 
Eagle’s medium (DMEM, Sigma-Aldrich, Munich, Germany) supplemented with 7.5% FBS, 
2 mM L-glutamine, 100 units/ml penicillin and 100 µg/mL streptomycin. Cultures were 
maintained at 37 °C in a humidified atmosphere containing 5% CO2. After one week in 
culture, the dermis pieces were removed and the outgrown fibroblasts sub-cultivated when 
confluent. Fibroblasts in passage 1 were trypsinized, resuspended in DMEM supplemented 
with 10% dimethyl sulfoxide (DMSO) and frozen until needed for further experiments. For 
every experiment, cells (passage 2-3) from three different donors were pooled. To generate 
myofibroblasts, fibroblasts were serum-starved for 72h followed by 96h of stimulation with 
10 ng/ml TGF-β1. 
2.2.1.2. 3D Cultivation of Myofibroblasts 
Primary human fibroblasts were trypsinized and adjusted to a concentration of 2*106 cells/ml 
in FBS. Collagen type I was mixed with Hank’s Buffered Saline Solution (HBSS) followed 
by pH neutralization with 1 M NaOH. Subsequently, the cell suspension was combined with 
the collagen solution in a 1:1 ratio and poured into a cell culture insert (3 µm pore size) for 
6-well plates with a growth area of 4.2cm2. Upon gel solidification, fibroblast growth medium 
was added, the system transferred to an incubator with 5% CO2 and 95% humidity and the 
medium changed every second day. After a cultivation period of 7 days, medium was 
supplemented with 10 ng/ml TGF-β for 72h. Subsequently, models were serum starved for 
24h or incubated with conditioned medium (CM) from adipocytes. 
2.2.1.3. Hypertrophic Scar & Keloid Fibroblast Isolation 
Isolation of fibroblasts from hypertrophic scars and keloids as well as their cultivation was 
conducted in the lab of Prof. Dr. Susan Gibbs at the Department of Molecular Cell Biology 
and Immunology at Vrije Universiteit Medical Center (VUmc), Amsterdam, Netherlands. 
Hypertrophic scars and keloid fibroblasts were isolated from skin samples of patients 
undergoing scar removal via excision. The discarded scar tissue was used in anonymous 
fashion in compliance with the VU University Medical Center’s ethical guidelines and the 
“Code for Proper Use of Human Tissues” in accordance with the Dutch Federation of 





Medical Scientific Organizations (see www.fmwv.nl). Scarred tissue was washed in PBS, 
minced into pieces of 0.5 cm² and placed on gauze soaked with dispase II solution (1U/ml 
in PBS). Following overnight incubation at 4 °C, the dermis was separated from the 
epidermis by using forceps. Subsequently, dermis pieces were incubated in a dispase 
II/collagenase II solution (10 mg/ml, 2.5 h, 37 °C) with manually shaking every 15 minutes. 
After a first filtration using a drip chamber (Beldico, Marche-en-Famenne, Belgium), cell 
solutions were filtered again by using cell strainers (100 µm and 70 µm). After centrifugation 
(5 min, 4 °C, 300 g), cells were counted and cultures were maintained in DMEM, containing 
7.5% FBS, 100 units/ml penicillin and 100 µg/mL streptomycin (37 °C, 5% CO2) and used 
for experiments in passages 2-3. 
2.2.1.4.ASC Isolation 
Adipose-derived stem cells (ASCs) were isolated from adipose tissue obtained from breast 
reconstruction and abdominal plastic surgeries (approved by the ethics committee of the 
Charité–Universitätsmedizin Berlin, Germany, EA2/121/15, with patient’s consent). Adipose 
tissue was washed in PBS, minced and incubated with a collagenase mix composed of 1 
mg/ml collagenase type I, 4% BSA and 1% penicillin/streptomycin for 50 min at 37 °C under 
agitation. Every 10 min tubes were shaken manually. The cell suspension was then passed 
through 100-µm and 70-µm strainers, centrifuged (300 g, 5 min) and seeded in DMEM/F12 
supplemented with 10% FBS, 100 units/ml penicillin and 100 µg/mL streptomycin. A 
medium change was performed the following day to remove debris. For induction of 
adipogenesis, ASCs inpassage 2-3 were further cultivated in DMEM/F12 supplemented 
with 10% FBS, 10 µg/mL insulin, 1 µM dexamethasone, 0.5 mM IBMX, and 1% 
penicillin/streptomycin for 14 days. 
2.2.1.5. Conditioned Medium Preparation 
For CM preparation, ASC and induced adipocytes were used in passage 2-3 and grown 
until confluence. To obtain conditioned medium (CM) from ASCs and adipocytes, cells were 
cultivated and differentiated as described previously. After washing in PBS, ASC and 
adipocyte culture media were replaced with serum-free media for 24h to avoid FBS 
contamination. Subsequently, CM was collected, centrifuged and stored at -80 °C until 
further use. 
2.2.1.6. Incubation with Conditioned Medium 
Confluent cell layers of myofibroblasts or fibroblasts isolated from hypertrophic scars were 
washed twice with PBS and then incubated with CM from either ASCs or adipocytes. 
Following 24h, cells for harvested and used for subsequent analysis. Myofibroblasts 
cultured in standard serum-free medium served as the control.  




2.2.1.7. Transwell and Direct Co-Culture Cultivation  
ASCs were seeded on a cell culture insert (3 µm pore size, PET membrane, Corning, 
Amsterdam, Netherlands) with a growth area of 4.2 cm2 in a 6-well cell culture plate and 
cultivated either in adipogenic differentiation medium or ASC growth medium for 14 days. 
In parallel, fibroblasts were differentiated into myofibroblasts (see 0) in a 6-well plate. Upon 
completed differentiation, the cell culture insert seeded with ASCs or adipocytes was 
transferred onto the 6-well plate pre-seeded with myofibroblasts. After 24h, myofibroblasts 
were harvested for further analysis.  
The direct co-culture was achieved by differentiating ASCs into adipocytes in a 6-well cell 
culture plate. After 14 days of cultivation, equal amount of myofibroblasts were added for 
24h. Myofibroblasts as well as adipocytes alone served as a control.  
2.2.1.8. Inhibition Studies 
Inhibition studies using two different antagonists were performed with the PPARγ inhibitor 
GW9662 (1 µM) or the BMP receptor type I antagonist LDN-193189 (200 nM). GW9662 is 
an irreversible antagonist that binds to the ligand binding site of PPARɣ thereby inhibiting 
its activity. The dorsomorphin derivate LDN-193189 on the other hand is a highly selective 
to the BMP receptor type I thereby inhibiting signaling through this pathway. Monolayers of 
myofibroblasts and hypertrophic scar fibroblasts were pretreated either with 1 µM GW9662 
or 200 nM LDN-193189 for 30 min followed by 24 h incubation with CM from adipocytes. 
Cells cultured in serum-free medium served as the control. 
2.2.2.  Trilineage Differentiation of ASCs 
2.2.2.1. Adipogenic Differentiation 
ASCs were subjected to the adipogenic differentiation (see details above) cocktail for 14 
days. In particular, dexamethasone is a glucocorticoid that functions as an inducer of 
C/EBPα. IBMX increases the intracellular cAMP concentration and insulin is known to mimic 
the insulin-like growth factor thereby activating PPARɣ. To verify the presence of in vitro 
differentiated adipocytes, lipid droplets were visualized by the lipophilic dye Oil Red O. The 
cells were washed with PBS followed by fixation in 4% PFA for 10 min. After an additional 
washing step, cells were incubated in 0.5% Oil Red O staining solution for 30 min. 
Adipocytes were then washed in water until staining solution was removed and imaged with 
a phase contrast microscope (Axiovert 135, Carl Zeiss, Jena, DE). 
2.2.2.2. Osteogenic Differentiation 
Osteogenesis was encouraged by cultivating ASCs for 14 days in differentiation medium 
containing 10% FBS, 0.1 µM dexamethasone, 50 µM ascorbate-2-phosphate and 10 mM 
β-glycerophosphate. Successful differentiation was verified by calcium depositions 





visualized by Alizarin Red staining. Cells were washed, fixed and incubated with 40 mM 
Alizarin Red staining solution for 20 min. Following washing, cells were imaged with a phase 
contrast microscope (Axiovert 135, Carl Zeiss, Jena, DE). 
2.2.2.3. Chondrogenic Differentiation 
For chondrogenic induction, ASCs were cultivated using the micromass technique. Since 
chondrocytes rapidly lose their phenotype in culture, specific conditions need to be created 
to form chondrocytes from precursor cells. Therefore, a high-density cultivation is necessary 
resulting in cell condensation and subsequently, ECM deposition (Archer et al., 1985). 
Micromasses were achieved by pipetting 10 µl of cell suspension containing 100,000 ASCs 
into wells of a 6-well cell culture plate. After 2 h, ASC growth medium was added. 24h later, 
the culture medium was switched to chondrogenic differentiation medium containing 1% 
FBS, 6.25 µg/mL insulin, 10 ng/mL TGF-β1 and 50 nM ascorbate-2-phosphate. After 14 
days, chondrogenic differentiation was verified by Alcian Blue staining. Alcian Blue stains 
acidic polysaccharides such as glycosaminoglycans in cartilages. 
2.2.3.  Western Blot 
For the investigation of various target protein concentrations in myofibroblasts, treated cells 
were washed in ice-cold PBS. Subsequently, myofibroblasts were lysed in 
radioimmunoprecipitation assay (RIPA) buffer for 30 min on ice, harvested and centrifuged 
(13,000 g, 30 min, 4 °C). Protein concentration was calculated using the Pierce® BCA 
Protein Assay Kit. Subsequently, 20 µg of protein lysate was prepared for sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE separates proteins 
according to their molecular mass based on their different migration rate through a gel under 
the influence of an electrical field. Since proteins with the same molecular weight would 
migrate differently depending on their charge and 3D structure, SDS is used. SDS is a 
detergent that, together with heat, disrupts the tertiary structure of proteins and coats the 
proteins with a negative charge. Therefore, samples were diluted in standard SDS-PAGE 
sample buffer supplemented with 100 mM dithiothreitol (DTT) and boiled at 95 °C. DTT is 
a reducing agent that breaks down protein-protein disulfide bonds. In parallel, gels were 
prepared for SDS-PAGE (see Table 1).  
Table 1: Running and Stacking gel composition for SDS-PAGE. 
 dH2O Acrylamid Gel buffer SDS (10%) 
Running Gel 4.1 ml 3.3 ml 2.5 ml 2 M Tris 
(pH 8.8) 
0.1 ml 








After mixing components, 50 µl ammonium persulfate (APS) and 10 µl TEMED were added 
to the running gel for polymerization and quickly poured into gel cassettes. Following 
running gel solidification, the stacking gel was added, and an appropriated comb was 
inserted. Protein samples were now subjected to SDS-PAGE (150 mV, 60-90 min). After 
separation, proteins were transferred onto nitrocellulose membranes (0.45 µm pore size) 
using a semi-dry transfer system (Bio-Rad, Munich, DE). Therefore, gel and membrane 
together with blotting pads were layered in a transfer cassette. By applying electrical load 
(200 mA, 30 min), the negatively charged proteins transfer onto the membrane. 
Subsequently, the membrane was blocked in Tris-buffered saline containing 0.1% Tween-
20 (TBST) supplemented with 5% skimmed milk powder or 5% BSA for 1h at room 
temperature to reduce the amount of unspecific binding of proteins. The membrane was 
further incubated with primary antibodies, targeting the protein of interest, diluted in 1:1000 
in TBST with 5% skimmed milk at 4 °C overnight (see 2.1.4.). Following washing in TBST, 
anti-rabbit or anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibodies 
were applied for 1h at room temperature. The blots were washed again, developed using 
SignalFire™ (Enhanced ChemiLuminescent) ECL reagent and visualized with a PXi/PXi 
Touch gel imaging system. Due to the interaction of the ECL substrate with the HRP-
conjugate a signal is generated reflecting the amount of target protein in the sample. 
Immunoblotting quantification was performed using ImageJ software. ImageJ was applied 
to analyze protein expression via densitometry. Target protein intensity was compared to 
that of the loading control (β-Actin or β-Tubulin). 
2.2.4.  Cellular Subfractionation 
To separate the nuclear and cytoplasmic fractions of myofibroblasts, an NE-PER Nuclear 
and Cytoplasmic Extraction Reagents Kit was used. Prior to cellular subfractionation, 
myofibroblasts were stimulated with adipocyte-CM for 24h or maintained in serum-free 
medium (control). Subsequently, the cells were trypsinized and centrifuged (500 g, 3 min), 
and the cell pellets were further processed according to the manufacturer’s instructions. 
2.2.5.  Enzyme-linked Immunosorbent Assay (ELISA) 
In order to analyze a potential BMP secretion of ASCs and adipocytes into CM, various 
sandwich ELISAs were performed. Therefore, collected CM from ASCs and adipocytes 
were analyzed by using human BMP 2, 4, 6 and 7 ELISA Kits according to the 
manufacturer's instructions. Here, 96-well plates have been pre-coated with a target-
specific antibody. Subsequently, samples or standards are applied and bind to the 
immobilized antibody. An additional, secondary antibody is used to generate a measurable 
signal. This HRP-linked antibody binds to the target-sample complex and thus, the intensity 





of the signal, measured at a wavelength of 562nm, directly reflects the amount of target 
protein. 
2.2.6.  Histology 
For histological analysis, myofibroblast 3D models were embedded in tissue freezing 
medium, shock-frozen with liquid nitrogen and subsequently cut into vertical sections (7 µm) 
using a cryotome (Leica Microsystems, Wetzlar, DE). Sections were then stained with 
hematoxylin and eosin (HE) in order to study their cellular structure. Hematoxylin stains 
nuclei blue whereas eosin colors eosinophilic structures such as the cytoplasm. First, 
sections were fixed in 4% formaldehyde. Subsequently, sections were processed as shown 
in Table 2. 
Table 2: Technical procedure of HE staining. 
Solution Application period [min] 
double-distilled H2O 0.5 
Mayer’s hemalum solution 5 
tap water 5 
Eosin G solution 0.5 
Ethanol 96% I 2 
Ethanol 96% II 2 
Ethanol 100% I 2 
Ethanol 100% II 2 
Roti®-Histol I 2 
Roti®-Histol II 2 
 
2.2.7.  Immunofluorescence  
In order to detect and localize α-SMA in myofibroblasts incorporated in the collagen matrix, 
cryosections were processed for immunofluorescence staining. Here, sections were fixed 
with 4% formaldehyde, blocked with normal goat serum (1:20 in PBS) and incubated 
overnight at 4 °C with primary antibodies (in PBS, 0.0025% BSA, 0.025% Tween 20, see 
0). Subsequently, slides were incubated for an additional hour at room temperature with 
secondary antibodies (1:400 in PBS, 0.0025% BSA, 0.025% Tween 20). Afterwards, the 
sections were embedded in DAPI mounting medium and analysed by fluorescence 
microscopy (BioZero, Keyence, Neu Isenburg, DE). 
 
 




2.2.8.  Flow Cytometry 
For verification of the ASC phenotype, the presence of the ASC-specific surface markers 
CD34 and CD105 and the hematopoietic stem cell marker CD45 was assessed via flow 
cytometry. Therefore, 100.000 ASCs in P0, P3 or P7 were trypsinized, washed and 
centrifuged (300 g, 5 min). After resuspension in binding buffer (PBS + 2mM EDTA + 0.5% 
BSA) and centrifugation, cells were incubated with FITC-linked antibodies (CD45 and 
CD105) or PE-linked (CD34) in binding buffer for 10 min on ice, respectively, as well as with 
an IgG1 isotype control (HRP-linked). Cell were assessed via flow cytometry with 
FACSCalibur (BD, New Jersey, US). Cell debris was excluded by forward and side scatter 
gating. Data were analyzed using WinMDI software (Version 2.8). 
2.2.9.  Annexin V/Propodium Iodide (PI) Staining 
To exclude any potential apoptotic effects of adipocyte-CM on myofibroblasts, an Annexin 
V/PI staining was performed. Annexin V binds to phosphatidylserine residues that appear 
on the cell surface as an early event in apoptosis. PI, in contrast, is dye that is normally 
impermeable for the cell membrane of viable cells but intercalates with the DNA of damaged 
cells. Myofibroblast were either incubated with CM from adipocytes or serum-free medium. 
As a positive control, cells were treated with 10% DMSO. After 24h, myofibroblasts were 
detached and centrifuged (300 g, 5 min). Subsequently, myofibroblasts were resuspended 
in binding buffer (PBS + 2mM EDTA + 0.5% BSA). After an additional centrifugation, 5 µl 
Annexin V-FITC in 195 µl binding buffer were added and cells incubated for 10 min at 4 °C. 
Myofibroblast were washed, centrifuged and again resuspended in binding buffer. Prior to 
analysis, 10 µl PI were added. Cells were assessed via flow cytometry with FACSCalibur 
(BD, New Jersey, US). After excluding debris by scatter gating, cells were gated for the two 
fluorophores Annexin V-FITC (FL1) and PI (FL2). Data were analyzed using WinMDI 
software (Version 2.8). 
2.2.10.   Glycerol-3-Phosphate Dehydrogenase (GPDH) Assay 
As an additional evaluation of adipocyte characteristics, a GPDH assay was performed (by 
Patrick Graff, supervised diploma student). Following 14 days of adipogenic differentiation, 
GPDH activity of the cells was measured using the Glycerol-3-phosphate dehydrogenase 
(G3PDH) assay kit according to the manufacturer’s instructions. GPDH is an enzyme that 
catalyzes the conversion between dihydroxyacetone phosphate and glycerol-3-phosphate 









2.2.11.   Real-time Quantitative Polymerase Chain Reaction (qPCR) 
For gene expression analysis, initially, RNA needed to be extracted from cells. Therefore, 
confluent cell layers were washed in PBS prior to 5 min incubation in RNA lysis buffer (from 
the InnuPREP RNA Mini Kit, Analytik Jena, Jena, Germany). After transfer of the lysed cell 
suspension to RNAse-free tubes, the RNA was isolated according to the manufacturer’s 
instructions. Prior to qPCR analysis, RNA samples needed to be converted into 
complementary DNA (cDNA) by using the retroviral enzyme reverse transcriptase. For 
cDNA synthesis, the iScript cDNA Kit (BioRad, Munich, DE) was used. Subsequently, qPCR 
samples were prepared using an iTaqTM Universal SYBR® Green Supermix Kit. The qPCR 
was performed using the LightCycler 480 (Roche, Mannheim, DE). The qPCR approach 
and the running protocol are listed in Table 3. For analysis of gene expression data, the 
relative quantification approach was used. Here, the obtained Cp-values are normalized to 
the housekeeping gene as a reference (glyceraldehyde-3-phosphate dehydrogenase, 
GAPDH). 
Table 3: Components and cycling conditions for qPCR 
qPCR reaction volume 
containing: 
Cycling conditions 
Temperature [°C] Duration 
[sec] 
Cycle number 
PCR water 2 µl 95 300 1 × 
Forward primer (10 
µM) 
0.5 µl 95 10  
45 × 
Reverse primer (10 
µM) 
0.5 µl 60 10 
SYBR green master 
mix 
5 µl 72 10 






40 10  
4 indefinite  
 
2.2.12.   Bromodeoxyuridine (BrdU) Assay 
To assess potential effects of CM-incubation on the myofibroblast’s proliferation, the 
proliferation of in vitro differentiated myofibroblasts was measured. Following 24h 
incubation with adipocyte-CM, proliferation was analyzed by using the cell proliferation 




Elisa, BrdU Kit according to the manufacturer's instructions. This assay is based on the 
measurement of bromodeoxyuridine incorporation during DNA synthesis of cycling cells. 
2.2.13.   Scratch Assay 
The scratch assay is a very basic wound healing assay where a “wound” is created in a cell 
monolayer by scratching. After the scratch, cell migration and growth towards the gap is 
monitored. First, myofibroblast were grown in 6-well cell culture plates and after reaching 
confluency, the monolayer was scratched across the center of the well by using a 200 µL 
pipet tip. Following scratching, cells were washed, and serum free or conditioned medium 
from adipocytes was applied. Images were taken at 0h and 24h by using a phase contrast 
microscope (Axiovert 135, Carl Zeiss, Jena, DE). 
2.2.14.   Contractility Assay 
In order to measure their contractility, myofibroblasts were embedded in a collagen gel. 
Therefore, in vitro differentiated myofibroblasts were generated, trypsinized and mixed with 
a collagen type I solution to a final concentration of 1 mg/mL. Subsequently, the gel solution 
was poured into a 6-well cell culture plate and left for solidification for 20 min at room 
temperature. Carefully, gels were dissociated from the well by gently running the tip of a 
200 µl tip. 600 µl serum free or conditioned medium were added for 24h. Diameter change 
of gels was recorded using a digital camera (Fujifilm X 20, Fujifilm, Tokyo, JP)) from a fixed 
distance above the gel. Contraction was quantified by calculating the gel surface area using 
ImageJ. 
2.2.15.   DigiWest® 
For an in-depth analysis of myofibroblast protein expression, the high-throughput DigiWest® 
analysis was performed. Therefore, myofibroblasts were stimulated with adipocyte-CM or 
serum-free medium for 24h. Subsequently, cells were washed twice in ice-cold PBS, 
detached and then centrifuged at 4 °C (2 min, 13,000 g). This description of the DigiWest® 
protein profiling procedure as well as its realization was conducted by NMI TT 
Pharmaservices as described previously (Treindl et al., 2016, Hoerst et al., 2019). Briefly, 
SDS-PAGE and Western blotting onto PVDF membranes was performed using the 
NuPAGE system (Life Technologies, Darmstadt, Germany). Blots were washed in PBS 
containing 0.1% Tween-20 (PBST). The proteins were biotinylated on the membrane using 
NHS-PEG12-Biotin in PBST and then washed in PBST and dried. Each sample lane was 
sliced into 96 fractions of 0.5 mm each, and the proteins were eluted in 96-well plates using 
elution buffer (8 M urea, 1% Triton-X100 in 100 mM Tris-HCl, pH 9.5). The eluted proteins 
from each molecular weight fraction were loaded onto one distinct color of neutravidin-
coated MagPlex beads (Luminex Corporation, Texas, USA) and pooled afterwards. A total 
of 10 µg of protein per cell sample was used for 96 different antibody incubations. Aliquots 





of the DigiWest® bead mixes were added to 96-well plates containing assay buffer 
(Blocking Reagent for ELISA (Roche, Penzberg, Germany)) supplemented with 0.2% milk 
powder, 0.05% Tween-20 and 0.02% sodium azide. After the assay buffer was discarded, 
diluted primary antibodies were added (see Appendix, Table 6). Following overnight 
incubation, bead mixes were washed twice with PBST, and phycoerythrin-labeled diluted 
secondary antibodies were added. Beads were washed twice, and assay results were 
measured on a Luminex FlexMAP 3D system. Antibody-specific signals were quantified 
using the DigiWest® data analysis tool to identify the peaks of correct molecular weight and 
to calculate peak areas. For comparative analyses between the samples, protein 
expression values were normalized to the total protein amount. 
2.2.16.   Mass Spectrometry 
Liquid chromatography/electron spray ionization mass spectrometry (LC/ESI–MS) was 
performed by Dr. Oliver Klein (Charité-Universitätsmedizin Berlin) as described previously 
(Becker et al., 2018, Hoerst et al., 2019). Also, the description of this method section was 
provided by Dr. Oliver Klein. Briefly, 1 ml of CM from three independent donors (A, B, C) 
was rebuffered in Amicon® Ultra centrifugal filters with 0.11 mM CHAPS (0.05 M Tris –HCL 
(pH 7.5) / 0.05 M KCL, 20% glycerin), 8 M urea/0.1 M/Tris-HCL (pH 8.5) and 50 mM 
ammonium bicarbonate (ABC, Sigma-Aldrich, Munich, Germany) to a finale volume of 40 
µl. Subsequently, 5 0 µl of 0.2 µg/µL trypsin (Promega, Mannheim, Germany) in 50 mM 
ABC was added and incubated with the sample overnight at 37 °C. Peptides were extracted 
with 60 µl of 0.1% TFA and directly analyzed by LC/ESI–MS. Peptide separation was 
performed (2-60% acetonitrile/ in 0.1% formic acid, flow rate 400 nl/min) using an analytical 
UHPLC system (Dionex Ultimate 3000 RSLC, Thermo-Fisher, Waltham, MA, USA) and 
analyzed with an ESI-QTOF mass spectrometer (Impact II, Bruker Daltonics, Billerica, MA, 
USA). Mass spectra were evaluated using MASCOT software (version number 2.2, Matrix 
Science, Boston, MA, USA) by automatically searching the SwissProt 51.9 database 
(553474 sequences; 198069095 residues, Cambridgeshire, UK). The MS/MS ion search 
was performed with the following set of parameters: (i) taxonomy, Homo sapiens (human) 
(20172 sequences); (ii) proteolytic enzyme, trypsin; (iii) maximum of accepted missed 
cleavages, 2; (iv) mass value, monoisotopic; (v) peptide mass tolerance, 10 ppm; (vi) 
fragment mass tolerance, 0.05 Da; and (vii) variable modifications, oxidation of methionine. 
Only proteins with scores corresponding to p<0.05 and with at least two independent 
peptides were considered. Visualization of protein interaction networks was performed with 
the String database using a high confidence interaction score (0.7) and experiments, 
databases, gene fusion and neighborhood as active interaction sources. GO enrichment 




analysis was performed using the open access platform Term Finder with cellular 
component as the ontology aspect. 
2.2.17.   Statistical Analysis 
Statistical tests were conducted by using the GraphPad Prism software (GraphPad 
Software, La Jolla, CA). The data from at least three independent experiments are 
presented as the means ± standard error of the mean (SEM). Significance was determined 
with a one-sample t-test followed by Bonferroni correction for multiple testing; *p ≤ 0.05, 
and **p ≤ 0.01. Each sample (CM ASC or CM adipocytes) was tested against the control 






3.1. Generation & Characterization of ASCs and Adipocytes 
First, the cultivation conditions for ASCs and in vitro differentiated adipocytes needed to be 
established. The adipose tissue from plastic surgery was either obtained as a lipoexcision 
or liposuction. Subsequently, cell isolation was performed by enzymatic digestion via 
collagenase type I followed by centrifugation resulting in the SVF. No difference was seen 
with regard to the cell yield when comparing liposuction and lipoexcision giving 
approximately 200,000 cells per gram tissue (Fig. 9). 
 
Fig. 9: Analysis of stromal vascular fraction yields from lipoexision or liposuction. 
Adipose tissue was obtained from lipoexcision or liposuction and subsequently minced, subjected to 
collagenase digestion followed by centrifugation and counted. Data are represented as mean ± SEM, 
n = 4-6. Assay performed by P. Graff (supervised as a diploma student). 
 
ASCs were then selected from the SVF by their plastic adherence and their identity was 
confirmed by verifying the high expression of the mesenchymal surface markers CD34 and 
105 and low expression of the hematopoietic marker CD45 (Fig. 10a). Furthermore, their 
potential of trilineage differentiation into adipocytes, osteoblasts and chondrocytes (Fig. 
10b-d) was successfully examined. Here, adipogenic differentiation of ASCs was verified 
by Oil Red O staining, osteogenic differentiation by Alizarin red staining and chondrocytes 
were stained with Alcian Blue. Effective differentiation after 14 days of cultivation in 
adipogenic differentiation medium was on the one hand verified by the presence of lipid 
droplets (Fig. 11b). On the other hand, in vitro differentiated adipocytes were analyzed for 
specific target gene expression as well as for their glycerol-3-phosphate dehydrogenase 
(GPDH) activity (Fig. 11). 





Fig. 10: Verification of adipose-derived stem cell (ASC) characteristics. 
a) ASCs in passages 0, 3 and 7 were analysed by flow cytometry for the expression of characteristic 
surface markers (  CD 34,  CD 105) and low expression of CD45 ( ). Data are represented as 
mean ± SEM, n = 3-4. (b) Adipogenic differentiation of ASCs was verified by Oil Red O staining, (c) 
osteogenic differentiation by Alizarin Red staining and (d) chondrogenic differentiation by Alcian Blue 
staining. Control = DMEM/F12 + 10% FBS (left panel), differentiation (right panel). Scale bar = 100 
μm. (Hoerst et al., 2019) 
 
Notably, adipocytes revealed an increased gene expression for the transcription factors 
PPARγ and CEB/Pα and the adipogenic factors adiponectin and leptin compared to their 
precursors. Moreover, a significant increase in the GPDH activity was detected, an enzyme 







Fig. 11: Characterization of in vitro differentiated adipocytes. 
Following 14 days of adipogenic differentiation relative mRNA levels for PPARγ, CEB/Pα, 
adiponectin and leptin were assessed (a) as well as the GPDH activity compared to ASCs (b). PPARγ 
= peroxisome proliferator-activated receptor gamma, CEB/Pα = CAAT enhancer binding protein 
alpha, ASCs = adipose-derived stem cells, GPDH = glycerol-3-phosphate dehydrogenase. Data are 
represented as SEM, n= 3. GPDH assay was performed by P. Graff (supervised as an diploma 
student). 
 
3.2. Myofibroblast Generation & Characterization 
For investigating potential effects of ASCs or in vitro differentiated adipocytes on scarring, 
an appropiate cellular system had to be found. Since the in vitro differentiation of fibroblasts 
into myofibroblasts by the addition of TGF-β1 is a common experimental design, this 
approach was chosen (Fig. 12).  
 
Fig. 12: Myofibroblast generation by TGF-β1 stimulation. 
Human juvenile dermal fibroblasts were treated for 72h with TGF-β1 (2, 5, 10 ng/mL) and analyzed 
for de novo expression of α-SMA expression by Western Blot and immunofluorescence. (a) 
Representative Western Blot and semi-quantification by densitometry showing the α-SMA 
expression compared to β-Tubulin. (b) Representative immunofluorescence pictures after TGF-β 
treatment with α-SMA (green) and DAPI (blue). Scale bar = 50 µm. Ctrl = Control, α-SMA = alpha-
smooth muscle actin, TGF-β1 = transforming growth factor beta 1. Data are presented as SEM, n=3. 




First, the optimal cultivation conditions for the generation of myofibroblasts needed to be 
studied. By the addition of increasing concentrations of human recombinant TGF-β1 to 
juvenile dermal fibroblasts, an enhanced α-SMA expression was observed accordingly (Fig. 
12). More precisely, α-SMA protein expression was studied by Western Blot analysis and 
immunofluorescence. Interestingly, fibroblasts treated with 10 ng/ml TGF-β for 72h revealed 
an α-SMA positive phenotype with α-SMA being incorporated into stress fibers reflecting 
the myofibroblasts as a contractile smooth muscle-like cell type (Fig. 12b). Therefore, the 
condition with 10 ng/ml TGF-β1 for 72h was chosen as an optimal requirement for 
myofibroblast generation.  
3.3. Co-cultivation of Adipocytes and Myofibroblasts 
Following the establishment of optimal culturing conditions of ASCs and adipocytes as well 
as myofibroblasts, a suitable model for studying their crosstalk was required. Analyses of 
intercellular communications allow for the application of several co-culture techniques 
summarized in Fig. 13. The main difference between these conditions lies in the direct or 
in-direct contact of the cells. Within a direct co-culture, the cell membranes of two cell types 
are in direct contact thereby allowing the exchange of cellular components via distinct 
junctions in the cell membrane. In contrast to that, the use of conditioned medium or a 
transwell system enables the interaction via soluble factors thereby representing paracrine 
effects of the cells. 
 
 
Fig. 13: Schematic overview of different co-culture approaches. 
Myofibroblasts were grown as monolayers and stimulated by adipocytes via conditioned medium or 










In this study, all three concepts were tested with myofibroblasts being exposed to co-
cultures with either adipocytes or ASCs. (Fig. 14). As being the main target, myofibroblasts 
gene expression was examined after 24h exposure to CM from adipocytes, shared medium 
with adipocytes in a transwell system or after direct contact to adipocytes (Fig. 14 a, b).  
 
Fig. 14: Co-cultivation approaches of myofibroblasts with adipoytes or ASCs. 
(a) Myofibroblasts were treated for 24h with adipocyte-CM , cultivated in a transwell with adipocytes 
 or exposed to adipocytes in a direct co-culture  for 24h, and subsequently analyzed for their 
gene expression of α-SMA (alpha-smooth muscle actin), Col 1 (collagen 1), Col 3 (collagen 3) and 
fibronectin compared to GAPDH. Data were normalized to FBM (fibroblast basal medium, dotted 
line). (b) Immunofluorescence image of the direct co-culture with α-SMA (red), BODIPY (green), 
DAPI (blue). Scale bar = 50 µm. (c) Myofibroblasts were co-cultivated with adipose-derived stem 
cells (ASCs) with the same approaches as described in (a). Data are presented as SEM, n = 3. 
 
Gene expressions for the ECM components collagen 1, collagen 3 and fibronectin were 
analyzed as well as the myofibroblast marker α-SMA. Interestingly, all genes showed a 
major decrease in their expression when CM was added but not in the presence of 
adipocytes in a transwell or in direct contact. When myofibroblasts were co-cultivated with 
ASCs, interestingly, the CM treatment induced a reduction in characteristic myofibroblasts 
gene expression as well but less distinct (Fig. 14c). After this initial screen, the CM 
approach was pursued for further testing.  




3.4. Phenotypic Changes in Myofibroblasts following CM Exposure 
For investigating CM-induced changes in myofibroblasts, myofibroblasts protein expression 
was studied for characteristic attributes including α-SMA and the ECM proteins collagen 1 
and 3. Interestingly, incubation of myofibroblasts with adipocyte-CM for 24h resulted in 
significantly reduced expression of α-SMA (-29.5% ± 4.9%; Fig. 15a). Further, a clear trend 
towards reduced deposition of collagen 1 (-66.4% ± 16.4%; Fig. 15c, p = 0.056) and 
collagen 3 (-41.3% ± 17.1%; Fig. 15e, p = 0.073) was observed (Hoerst et al., 2019). 
Myofibroblast treatment with CM from ASCs also yielded in a decreased expression of those 
three proteins, however, not comparable to adipocyte-CM. Since myofibroblasts were 
generated in vitro, another cell source was included in the CM-studies which was directly 
obtained from scar tissue. Hence, fibroblasts from hypertrophic scars were isolated (at 
VUmc in Amsterdam, Netherlands, in cooperation with Prof. Dr. Susan Gibbs) and 
incubated with CM equally. In this case, the effect of adipocyte-CM was even more 
pronounced with a significantly downregulated expression for -SMA and collagen 3, and a 
clear tendency for reduced collagen 1 (Fig. 15b with - 80.5% ± 9,6%; d with - 61,7%; f with 
- 51.1% ± 9.6%). Notably, incubation with ASC-CM resulted again in less distinct effects 







Fig. 15: α-SMA expression is significantly downregulated in myofibroblasts and 
hypertrophic scar fibroblasts following incubation with adipocyte-CM. 
Representative Western blots and associated semi-quantification by densitometry showing the 
relative protein expression of α-smooth muscle actin (α-SMA), collagen 1 (COL1) and collagen 3 
(COL3) in TGF-β-induced myofibroblasts (a, c, e) and hypertrophic scar fibroblasts (b, d, f) after 
exposure to conditioned medium (CM) from adipocytes and adipose-derived stem cells (ASCs). Ctrl 
= control, serum-free medium treatment. The data are presented as the mean ± SEM; n = 3-5 (*p ≤ 
0.05, and **p ≤ 0.01). (Hoerst et al., 2019) 




Since CM incubation resulted in a tremendous reduction of myofibroblast attributes, more 
features of those cells were investigated. Considering the contractile activity of 
myofibroblasts during wound healing, implementation of this parameter into the CM studies 
was inevitable. Therefore, myofibroblasts were seeded in a collagen matrix and stimulated 
with adipocyte-CM. Interestingly, myofibroblast contraction was reduced in the presence of 
adipocyte-CM (-37.8% ± 1.6%) indicating a reversal of this myofibroblast characteristic as 
well (Fig. 16a, b). However, myofibroblast proliferation and migration remained unaffected 
(Fig. 16c, d) (Hoerst et al., 2019). 
 
 
Fig. 16: Conditioned medium (CM) reduced myofibroblast contractility but did not affect 
myofibroblast proliferation or migration 
(a) Representative images of in vitro differentiated myofbroblasts, 24 h after seeding in collagen gels 
on Ctrl (= control, serum-free) medium or adipocyte-conditioned medium (CM). (b) Contraction of 
gels represented as percentage of contraction compared to original volume. (c) Myofibroblast 
proliferation, assayed by BrdU incorporation, after 24 h incubation with control or conditioned medium 
from adipocytes. (d) Representaive images of myofibroblast migration following scratching and CM-









Additional to characteristic myofibroblast features, potential side effects of adipocyte-CM on 
cell viability were considered. Therefore, an Annexin V staining for the detection of apoptotic 
cells and a propidium iodide (PI) staining for potential necrosis was performed (Fig. 17). 
Myofibroblasts cultured on basal medium (95.79%) or with adipocytes-CM (95.87%) were 




Fig. 17: Myofibroblasts treated with adipocyte-CM were negative for Annexin V/PI staining.  
In vitro generated myofibroblasts were left untreated (a) or subjected to conditioned medium (CM) 
from adipocytes (b) followed by Annexin V/PI staining and flow cytometry analysis. Annexin V FITC-
A vs Propidium Iodide-A (PI-A) plots from show the populations corresponding to viable and non-
apoptotic (Annexin V–PI–, left lower), early (Annexin V+PI–, right lower), and late (Annexin V+PI+, right 
upper) apoptotic cells. DMSO-treated myofibroblasts served as a positive control (see Appendix Fig. 
30). 
 
3.5. TGF-β Signaling in Myofibroblasts  
Due to the remarkable results of CM, particularly from adipocytes, on myofibroblasts and 
hypertrophic scar fibroblasts characteristics, further insights into intracellular changes of 
both cell types were desirable. Since TGF-β signaling plays a pivotal role in myofibroblast 
generation and perpetuation, canonical and non-canonical TGF-β signaling elements were 
addressed in subsequent studies. Here, again, myofibroblasts and hypertrophic scar 
fibroblasts were incubated with CM from ASCs and adipocytes and analyzed for regulations 
in their protein expression. Notably, no significant alterations in phosphorylated Smad 2/3 
were observed (Fig. 18a) indicating that the canonical TGF-β pathway is not affected by 
CM.  





Fig. 18: Protein expression of SMAD 2/3 and stress-activated protein kinase/Jun-amino-
terminal kinase SAPK/JNK in myofibroblasts and hypertrophic scar fibroblasts. 
Representative Western blots and relative protein expression semi-quantified by densitometry of 
myofibroblasts (A) and hypertrophic scar fibroblasts (B) following incubation with conditioned medium 
(CM) from adipose-derived stem cells (ASCs) and adipocytes. Protein expression analyses of 
phosphorylated proteins compared to SMAD 2/3 and SAPK/JNK are shown (Ctrl = control, serum-
free medium treated). Data are presented as mean ± SEM, n = 3. (Hoerst et al., 2019) 
 
However, since TGF-β also signals through Smad-independent pathways, such as via 
MAPKs, three target proteins were investigated. Like Smad 2/3, phosphorylated SAPK/JNK 
showed no regulated expression pattern as well upon CM stimulation (Fig. 18b). By 
contrast, a significant decrease in phosphorylated ERK 1/2 was found in myofibroblasts and 
hypertrophic scar fibroblasts following CM-incubation (Fig. 19a, b). Similarly, a significant 
reduction in phosphorylated p38 levels (Fig. 19c, d) was observed. Again, adipocyte-CM 







Fig. 19: Non-canonical TGF-β signaling elements are reduced in myofibroblasts following 
CM incubation.  
Representative Western blots and relative protein expression (semi-quantified by densitometry) of 
phosphorylated ERK 1/2 (p-ERK 1/2) and phosphorylated p38 (p-p-38) in TGF-β-induced 
myofibroblasts (a, c) and hypertrophic scar fibroblasts (b, d) following incubation with CM from 
adipose-derived stem cells (ASCs) and adipocytes. Ctrl = control, serum-free medium treatment. The 
data are presented as the mean ± SEM; n = 3-5 (*p ≤ 0.05, and **p ≤ 0.01), (Hoerst et al., 2019). 
 
3.6. PPARγ Expression in Myofibroblasts 
Since a reciprocal, antagonistic relationship has been described for TGF-β and the nuclear 
receptor PPARγ, a potential contribution of PPARγ to the observed alterations in 
myofibroblasts induced by adipocyte-CM was considered (Fig. 20).  





Fig. 20: Antagonizing PPARγ abolishes the α-SMA reduction observed after exposure to 
adipocyte-CM. 
Representative Western blots and relative protein expression (semi-quantified via densitometry) of 
α-SMA in TGF-β-induced myofibroblasts (a) and hypertrophic scar fibroblasts (b) after preincubation 
with GW9962 followed by CM-treatment. β-Tubulin served as the loading control. (c) Representative 
Western blots and relative protein expression (semi-quantified by densitometry) of peroxisomal 
proliferator-activated receptor γ (PPARγ) after subfractionation of TGF-β-induced myofibroblasts. 
GAPDH served as the loading control for cytoplasmic fractions; Histone H3 for nuclear fractions. Ctrl 
= control, serum-free medium treatment. The data are presented as the mean ± SEM; n = 3 (*p ≤ 






Therefore, myofibroblasts and fibroblasts from hypertrophic scars were preincubated with 
the PPARγ antagonist GW9662 prior to exposure to CM. Interestingly, this preincubation 
with GW9662 completely abolished the α-SMA downregulation (Fig. 20a, b) indicating a 
possible role of PPAR for mediating the effects of CM from adipocytes (Hoerst et al., 2019). 
Furthermore, the influence of CM from adipocytes on the PPARγ expression in 
myofibroblasts was studied. More precisely, PPARγ expression before and after TGF-β-
induced myofibroblast exposure to adipocyte-CM was assessed by subfractionating 
allowing for an expression analysis in cytoplasmic and nuclear compartments separately. 
Indeed, an increased trend in PPARγ expression by 8% ± 2.4% in cytoplasmic extracts was 
observed and significantly increased PPARγ expression in nuclear fractions (14.6% ± 3.3%) 
(Fig. 20c) (Hoerst et al., 2019). 
3.7. CM Analysis of ASCs and in vitro differentiated Adipocytes  
Since the studies with CM, especially with CM generated from adipocytes, revealed 
promising effects on myofibroblasts and hypertrophic scar fibroblasts, further clarification of 
the CM content was necessary. Therefore, a Liquid Chromatography based mass 
spectrometry shotgun proteomics approach was conducted for both CM-ASCs and CM-
adipocytes (in cooperation with Dr. Oliver Klein from Charité-Universitätsmedizin Berlin). 
This approach demonstrated the secretion of 160 proteins from ASCs and 288 from in vitro 
differentiated adipocytes. A subsequent literature comparison revealed that 90 out of those 
288 proteins are commonly identified in adipocyte-CM (Fig. 21, (Hoerst et al., 2019, Ojima 
et al., 2016, Zvonic et al., 2007, Alvarez-Llamas et al., 2007, Zhong et al., 2010)). 
Interestingly, using a search tool for the retrieval of interacting genes and proteins, wound 
healing processes (GO: 0042060) were significant (p ≤ 0.01) enriched and included 23 
proteins. In addition, 5 of these proteins could be assigned to the GO term regeneration 
(GO: 0031099; Fig. 21, (Hoerst et al., 2019)). 
 








Fig. 21: Secretome analysis of in vitro differentiated adipocytes shows secretion of 288 
mediators. 
STRING analysis of the 90 out of 288 proteins that have been previously identified in the adipocyte 
secretome. Among these, 23 are associated with wound healing (red spheres) and 5 with 
regeneration (blue spheres) according to GO terms. The lines indicate known protein interactions 
based on curated databases (turquoise), experiments (pink), predicted interactions for neighborhood 
(green) or gene fusion (red). (Hoerst et al., 2019) 
 
In addition to the adipocyte secretome, the 160 identified proteins in ASC-CM were also 
compared to relevant literature (Rosenow et al., 2010, Zhong et al., 2010, Kim et al., 2015, 
Kim et al., 2010). Here, 41 proteins from our analysis were commonly found, but when 
subjected to STRING analysis and examined for the same GO terms, only 9 proteins were 
found to be associated to wound healing and none to regeneration (Fig. 22). Interestingly, 
7 proteins were associated with angiogenesis (GO:0001525). Even though a wide range of 
interesting and potential regenerative factors were identified in adipocyte CM, no conclusion 







Fig. 22: Secretome analysis of ASCs reveals less secreted proteins compared to adipocytes. 
STRING analysis of 41 out of 160 proteins found in previous literature. Here, only 9 proteins are 
associated with wound healing (red spheres) and angiogenesis (blue spheres) according to GO 
terms and none were found for regeneration. The lines indicate known protein interactions based on 
curated databases (turquoise), experiments (pink), predicted interactions for neighborhood (green) 
or gene fusion (red). 
 
3.8. BMP Signaling in Myofibroblasts 
Since the involvement of bone morphogenetic proteins (BMP)-2 and -4 in myofibroblast 
reprogramming has been recently shown (Plikus et al., 2017), BMP secretion by ASCs and 
adipocytes was analyzed via ELISA, and the results showed distinct levels of BMP-4 (Fig. 
23a), whereas BMP-2, -6 and -7 were not detected. To further analyze the role of BMP-4, 




TGF-β-induced myofibroblasts were preincubated with the BMP receptor type I inhibitor 
LDN-193189, which abolished the effects of adipocyte-CM, resulting in unchanged α-SMA 




Fig. 23: BMP-4 is involved in myofibroblast reprogramming. 
(a) Bone morphogenetic protein (BMP)-4 secretion from adipocytes and adipose-derived stem cells 
(ASCs) measured by ELISA (Ctrl = control, serum-free DMEM/F12). (b) Representative Western 
blots of α-SMA expression following TGF-β-induced myofibroblast preincubation with the BMP 
receptor inhibitor LDN-193189 prior to incubation with adipocyte-CM. (c) α-SMA protein expression 
in TGF-β-induced myofibroblasts after stimulation with 20 ng/mL recombinant BMP-4 or adipocyte-
CM. (d) Representative Western blots of p-SMAD 1/5/9 expression in TGF-β-induced myofibroblasts 
following adipocyte-CM incubation. The relative protein expression of target proteins was semi-
quantified by densitometry and compared with β-actin or β-tubulin expression. The data are 
presented as the mean ± SEM; n = 3-5 (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001) (Hoerst 






To verify the involvement of BMP-4, 20 ng/mL recombinant human BMP-4 was added to 
TGF-β-induced myofibroblasts and led to distinct α-SMA downregulation comparable to that 
induced by incubation with adipocyte-CM (Fig. 23c). In addition, activation of BMP 
signaling, and hence the phosphorylation pattern of the SMAD 1/5/9 complex, was analyzed 
(Fig. 23d). Indeed, the expression of phosphorylated SMAD 1/5/9 increased significantly in 
TGF-β-induced myofibroblasts following incubation with adipocyte-CM (Hoerst et al., 2019). 
3.9. Potential Myofibroblast Trans-differentiation into Adipocytes 
A recent study has indicated the potential of BMP-4 to induce adipogenic transformation of 
scar fibroblasts in vitro and in vivo (Plikus et al., 2017). In their in vitro experiments, the 
authors treated hypertrophic scar as well as keloid fibroblasts with BMP-4 to induce 
adipogenic commitment followed by a hormone cocktail mediating adipogenic 
differentiation. To test whether adipocyte-CM could induce a similar trans-differentiation, a 
similar study to Plikus report was performed. Following the protocol by Plikus et al., 
myofibroblasts as well as fibroblasts from hypertrophic scars and keloids (both scar cell 
types isolated and cultivated at Prof. Dr. Gibbs’ lab at the VUmc in Amsterdam, Netherlands) 
were stimulated with 20 ng/mL BMP-4 or adipocyte-CM for 48h, followed by further 
cultivation in adipogenesis medium for another 10 days. However, no lipid droplet formation 
or significant increases in characteristic adipogenic genes or proteins were observed (Fig. 
24). 





Fig. 24: Incubation with BMP-4 and conditioned medium (CM) did not induce myofibroblast 
trans-differentiation into adipocytes. 
(a) Representative images of hypertrophic scar fibroblasts following incubation with BMP-4 or 
adipocyte-CM and adipogenesis medium. Control (=Ctrl) cells were incubated in adipogenesis 
medium only. Scale bar = 100 µm. Relative mRNA levels for (b) peroxisome proliferator-activated 
receptor γ (PPARγ), (c) CCAAT-enhancer-binding protein β (CEBPβ), (d) Inhibitor of DNA binding 1 
(Id1) and (E) α-smooth muscle actin (α-SMA) in hypertrophic scar ( ) and keloid ( ) fibroblasts. 
Data are presented as mean ± SEM. n = 3 (Hoerst et al., 2019). 
 
Following these observations, another approach was tested. Since gene expression data 
are very time-dependent, a time course experiment for the first 24h of CM-treatment was 







Fig. 25: Time-course of myofibroblasts gene expression after adipocyte-CM or BMP-4 
stimulation. 
Relative mRNA expression for PPARγ (a), CEB/Pα (b), Id1 (c) and ZNF423 (d) compared to GAPDH 
and normalized to FBM (fibroblast basal medium, dotted line) in myofibroblasts follwoing 24h 
exposure to adipocyte-CM or 20ng/ml BMP-4. PPARγ = peroxisome proliferator-activated receptor 
gamma, CEBPα = CAAT enhancer binding protein alpha, BMP-4 = bone morphogenetic protein-4. 
ZNF423 = zinc finger protein 423. Data are presented as SEM, n=3. 
 
Here, myofibroblasts were stimulated for 3, 6 and 24h with adipocyte-CM and analyzed for 
target gene expression. For comparison of the adipocyte-CM impact, effects of 20 ng/ml 
BMP-4 for the three time points were analyzed in parallel. Notably, nuclear receptor PPARγ 
showed a time-dependent increase in mRNA levels triggered by adipocyte-CM as well as 
BMP-4. In contrast to that, reduced CEBPα mRNA expression was found at any point and 
for both conditions. However, both BMP-4 downstream targets Id1 and ZNF423 showed an 
augmented gene expression after adipocyte-CM and BMP-4 stimulation. It is hardly 
surprising that BMP-4 induced a stronger increase in mRNA levels due to its high 
concentration compared to what was found in adipocyte-CM (110,5 ± 10.1 pg/ml, Fig. 23). 
3.10. High-throughput Analysis of Myofibroblast Protein Expression  
For a more comprehensive analysis of the effects of adipocyte-CM on TGF-β-induced 
myofibroblasts, a bead-based DigiWest® analysis, a high-throughput Western blot 




approach, was performed by Dr. Gerrit Erdmann and Anja Briese from NMI TT 








Fig. 26: High-throughput analysis of myofibroblast protein expression indicates distinct 
alteration of BMP and PPARγ signaling following incubation with adipocyte-CM. 
TGF-β-induced myofibroblast protein expression following adipocyte-CM stimulation was analyzed 
by the DigiWest® bead-based multiplex Western blot analysis. For clustering, ratios were calculated 
between CM-treated and untreated samples from each group followed by log2 transformation. 
Hierarchical clustering (HCL) was performed on the log2 transformed ratios using MeV 4.9.0 
Software. Each group represents a of pool cells from three independent donors (Hoerst et al., 2019).  
 
Hierarchical clustering (HCL) analysis revealed up- (yellow) or downregulation (blue) of 77 
proteins (Fig. 26). However, it must be noted that donor variability needs to be considered. 
Two out of three pooled myofibroblast samples showed significantly increased BMP-4 
protein expression after incubation with adipocyte-CM. Interestingly, the expression levels 
of the transcription factor CCAAT/enhancer-binding protein β (CEBPβ) and transcriptional 
coactivator Cbp/P300- interacting transactivator with Glu/Asp rich carboxy-terminal domain 
2 (CITED2), both of which are associated with PPARγ activation, were enhanced (Fig. 27a). 
The expression of phosphorylated ERK 1/2 was consistently reduced in all samples (Fig. 
27b), which confirms previous findings (Fig. 19a, b) (Hoerst et al., 2019).  
HCL analysis further indicated alterations in Wnt signaling elements, although currently no 
clear conclusion can be drawn because both inducers and inhibitors of Wnt pathways 
seemed to be modulated after myofibroblast incubation with adipocyte-CM. Notably, 
increased expression of plasminogen activator inhibitor (PAI)-1 and Notch-1 (Fig. 27c) were 
observed, both of which are associated with myofibroblast differentiation (Hoerst et al., 
2019). 
 





Fig. 27: Detailed expression levels of selected proteins from Fig. 26. 
Protein expression levels of (a) CITED2, BMP-4 and CEBPβ; (b) p-ERK 1/2 and p-JNK/SAPK; (c) 








3.11. Establishment of a 3D Myofibroblast Model 
After obtaining those promising results from a two-dimensional (2D) co-cultivation 
approach, an attempt for establishing a three-dimensional (3D) model was conducted. 
Since 2D cell culture experiments lack the complexity of the physiological human situation, 
a 3D model could represent a more reliable tool for investigating the given intricate 
structures of scarring. Therefore, a first approach consisting of myofibroblasts embedded in 
a 3D matrix was addressed. More precisely, dermal fibroblasts were incorporated into a 
collagen gel and placed onto a cell culture insert. Following 7 days of culture, fibroblasts 
were stimulated with TGF-β to obtain myofibroblasts. Subsequent incubation with 
adipocyte-CM resulted in a decreased α-SMA expression verified by Western Blot and 
immunofluorescence (Fig. 28). In view of those first results, this approach of a 3D 
myofibroblasts model holds the potential for further studies of myofibroblasts in a more 
complex environment. 
 
Fig. 28: Establishment of a 3D myofibroblast model. 
Dermal fibroblasts were seeded into a collagen gel and differentiated into myofibroblasts after 7 days 
cultivation. Following 24h exposure to adipocyte-CM, the myofibroblast model was subjected to 
further analysis. (a) Representative Western Blot of alpha smooth muscle actin (α-SMA) and β-
Tubulin with (b) semi-quantification by densitometry. (c) Histological and (d) immunofluorescence 






4.1. Suitable In Vitro Models for Studying Scar Regeneration 
So far, a large spectrum of experimental models ranging from simple monolayer cell culture 
experiments to 3D tissue-engineered models and animal models are available for 
investigating cellular communication. It seems to be a matter of course that a suitable model 
always depends on the fundamental question and that is, indeed, challenging for studying 
human scar regeneration. Scar models are essential for approaching questions such as the 
pathogenesis of scarring, identifying new drug targets or testing potential therapeutics. 
Naturally, human studies represent the ultimate approach and are required for the validation 
of potential novel therapeutics identified in animal or in vitro scar models. However, due to 
ethical issues and probably also due to interindividual differences with regard to the extent 
and duration of scar appearance, patients are rarely used for investigating the pathogenesis 
of abnormal scars (van den Broek et al., 2014). In an attempt to overcome the problems 
faced in patient studies, researchers have been trying to extrapolate results from animal 
studies. Even though a large number of models exist to study scarring, dealing with mice, 
rabbits, pigs and other animals, the basic skin physiology and immunology and hence, 
wound healing processes vary widely from the human situation (Hillmer and MacLeod, 
2002, Ramos et al., 2008, Seo et al., 2013, Seok et al., 2013). Therefore, those animals do 
not develop abnormal scars such as hypertrophic scars and keloids as observed in humans. 
The animal that shares most similarities with human skin physiology is the pig. Interestingly, 
porcine skin has a similar dermal-epidermal thickness ratio and epidermal lipid composition  
(Summerfield et al., 2015). Besides parameters, such as general structure, thickness and 
hair follicle content, pigs, especially the red Duroc pig, have been shown to develop 
hypertrophic scars similar to humans (Simon and Maibach, 2000). Zhu and colleagues 
presented scars in red Duroc pigs following deep dermal wounds with disorganized collagen 
bundles and characteristic nodule formation like in human hypertrophic scars (Zhu et al., 
2003). However, pigs are large animals, difficult to handle and expensive, probably just 
some of the reasons why the red Duroc pig has not become a gold standard of scar models 
(Ramos et al., 2008). To tackle the discrepancies between humans and animals, humanized 
animal models have been developed. Here, healthy human split-thickness skin grafts have 
been transplanted onto the back of nude mice to establish a hypertrophic scar mouse model 
(Momtazi et al., 2013, Yang et al., 2007a). Similarly, keloid skin has been transplanted onto 
nude mice (Estrem et al., 1987, Kischer et al., 1989, Shetlar et al., 1985). Since these mice 
are immune-deficient the chance of graft rejection is reduced. However, this 
immunodeficiency also means that the immune component of wound healing and scarring 
is only poorly represented (Seok et al., 2013). Along with ethical issues, the ideal solution 






in vitro studies is to use the conventional cell monolayer. This was, indeed, also applied in 
this thesis. First, the cultivation and differentiation of all cell types used in this study needed 
to be established. With regard to adipose tissue those were ASCs and adipocytes. While 
the ASC characterization by specific surface markers and their trilineage differentiation was 
implemented successfully (Fig. 10), the cultivation of adipocytes was challenging. Owing to 
their high lipid content, mature adipocytes in culture clump, float on top of the medium and 
therefore, do not get equal and sufficient access to the medium. As a result, most adipocytes 
undergo cell lysis within 72h after cell isolation (Zhang et al., 2000). One possible way to 
overcome these problems would be the ceiling culture, where adipocytes adhere to the top 
inner surface of a cell culture flask which is completely filled with medium. Although this 
method allows for the cultivation of adipocytes, however, treatments or co-cultivation 
approaches with other cell types remain challenging (Dong et al., 2015). Therefore, in the 
present study, adipocytes were in vitro differentiated from ASCs. By the verification of lipid 
droplets, adipocyte specific gene expression and an increased GPDH activity, successful 
adipocyte differentiation was confirmed (Fig. 11). However, it needs to be considered that 
in vitro differentiated adipocytes still vary from mature adipocytes, for instance by the fact 
that they contain multiple small lipid droplets instead of one large fat vacuole. Nonetheless, 
in vitro differentiated adipocytes present a valuable cellular model facilitating the study of 
differences between adipocytes and their precursors (Armani et al., 2010).  
In addition to ASCs and adipocytes, another cell type needed to be introduced which was 
the myofibroblast phenotype. Notably, in vitro myofibroblast generation based on TGF-β 
treatment has been shown before (Rønnov-Jessen and Petersen, 1993, Vaughan et al., 
2000). The successful in vitro differentiation was verified by de novo expression of the 
myofibroblast marker α-SMA (Fig. 12) as well as other specific features such as contractility 
(Fig. 16). Moreover, another primary source for scar fibroblasts was acquired by 
establishing a cooperation with the group of Prof. Dr. Susan Gibbs in Amsterdam, 
Netherlands, where hypertrophic scar and keloid fibroblasts were isolated and cultivated. 
To bring those different cell types together and study a potential intercellular crosstalk 
between adipose tissue and connective tissue cells, different co-culture approaches were 
investigated (Fig. 13). Here, only the CM approach revealed promising results by reducing 
myofibroblast characteristics. This is in line with previous studies that investigated the 
regenerative potential of ASCs and postulated paracrine effects of those cells (Kim et al., 
2007, Verhoekx et al., 2013, Spiekman et al., 2014). Interestingly, even more studies exist 
that addressed the characterization of cells isolated from scar tissue, especially 
hypertrophic scar and keloid-derived fibroblasts and keratinocytes (Funayama et al., 2003, 
Khoo et al., 2006, Lim et al., 2009, Phan et al., 2003). Even though all studies, including the 




present one, showed promising results and produced valuable insights into scar 
characteristics, the lack of physiological relevance of those very basic monolayer studies is 
obvious. Therefore, models with a three-dimensional (3D) structure would be ideal. With 
having the aim of this study in mind, there are two essential items that need to be considered 
about a suitable 3D model: on the hand, a complex model mimicking the fibrotic tissue 
structure of a native scar would be needed. On the other hand, a component that represents 
the injected adipose tissue needs to be integrated to study scar regeneration upon fat 
grafting. For both mentioned tissues, promising models already exist. For instance, 
fibroblasts have been seeded on a collagen lattice with biaxial load being applied 
subsequently to mimic mechanical tension in scar tissue (Derderian et al., 2005). With the 
discovery of an important crosstalk between keratinocytes and fibroblasts regarding ECM 
production (Ghaffari et al., 2009), organotypic skin equivalents have moved to the fore of 
studying scar pathogenesis. Skin equivalents where dermal fibroblasts were replaced by 
hypertrophic scar or keloid fibroblasts have been developed as well as models with an 
epidermis populated with keratinocytes derived from keloids (Chiu et al., 2005, Butler et al., 
2008, Bellemare et al., 2005). However, the use of those models for testing therapeutics is 
limited due to the lack of valid biomarkers (van den Broek et al., 2014). Interestingly, much 
progress on 3D models of adipose tissue has been made. Adipose tissue engineering has 
made great advantages with various synthetic and non-synthetic biomaterials being used. 
Synthetic polymers such as polylactic acid (Shanti et al., 2008), polyglycolic acid (Lin et al., 
2008), and the copolymer polylactic-co-glycolic acid (Kang et al., 2008) have been used 
with promising results supporting adipogenesis in vitro. Indeed, natural products are 
preferred with respect to biocompatibility as well as their mechanical and biological 
properties. Here, the use of materials found in the native ECM or generated by biological 
systems is favored, such as collagen and silk fibroin (Mauney et al., 2007). Although there 
are promising approaches and models for both players in this scar regeneration process, 
so far, no 3D model exists which combines both components, scar tissue and adipose 
tissue. To address this issue, first attempts have been made in this thesis to establish a 3D 
scar regeneration model. Due to the fact that scar-derived fibroblasts were only available in 
cooperation with the Gibbs lab in Amsterdam, the idea of a 3D myofibroblast model based 
on dermal normal fibroblasts grew. Since the Hedtrich lab is experienced in the 
development of skin equivalents, this established model was used as a template (Eckl et 
al., 2011, Küchler et al., 2011). Therefore, dermal juvenile fibroblasts were incorporated in 
a collagen gel and subsequently treated with TGF-β in order to generate myofibroblasts. 
Following successful generation verified by α-SMA expression, 3D myofibroblasts were 
treated with adipocyte-CM and a similar α-SMA downregulation was observed as in 






artificial. Other cellular components of fibrotic tissue such as endothelial cells or 
keratinocytes are missing as well as an immune component. Moreover, other ECM 
components and cytokines are not considered. The adipose tissue is also represented by 
CM only. Here, an additional 3D layer of adipocytes or ASCs in collagen, for instance, could 
be beneficial to mimic a complex 3D environment. In addition to the cellular simplicity of the 
model, the genetic predisposition factor that plays at least in keloids an important role, is 
not considered here. Also, existing scar models have a lifetime of only a few weeks while 
abnormal scars grow for months or even years. To conclude, for establishing a suitable in 
vitro scar regeneration model for studying the processes of cellular and matrix remodeling 
upon autologous fat grafting in human patients with pathological scars, there is still a long 
way to go. One solution for those limitations could be the new technology of organ-on-a-
chip that has been introduced in the last years (Baker, 2011, Giese et al., 2010, Huh et al., 
2010). Interestingly, the organ-on-a-chip system is based on engineered tissues that consist 
of multiple cell types interacting with each other. Even more importantly, those tissues are 
grown in a microfluidic chip which allows for an ideal and controlled supply of the organ. 
Recently, a WAT-on-a-chip has already been introduced (Loskill et al., 2017, Liu et al., 
2019). In addition, several skin-on-a-chip models have been reported (Ataç et al., 2013, van 
den Broek et al., 2017, Lee et al., 2017). Once a scar-on-a-chip model has been developed, 
an in-depth analysis of the ongoing process during scar remodeling could be followed 
thoroughly.  
Until then, and even though cell monolayer studies have their limitations, they provide a 
useful platform for studying intracellular signaling mechanisms. Here, their simplicity is an 
advantage since external influences such as the treatment with CM are directly reflected in 
the cell monolayer. In the present study, several intracellular changes have been observed 
in the myofibroblast following adipocyte-CM as well as ASC-CM incubation. Whether 
adipocytes or ASCs may have a greater influence on scar regeneration will be discussed in 
the next chapter.  
  




4.2.  Adipose Tissue and its Cellular Components as a Regenerative Tool 
Over the past years, new insights into the functionality and composition of adipose tissue 
have stimulated speculation about its regenerative potential (Hoerst et al., 2019). Transfer 
of adipose tissue, also known as fat grafting, lipografting or lipofilling, is widely recognized 
as a novel and promising technique for volume corrections, dermal rejuvenation and scar 
treatment (Klinger et al., 2013, Coleman and Saboeiro, 2007). As described in 1.2.3, clinical 
reports and trials on the beneficial effects of adipose tissue on fibrotic conditions emerge, 
however, less is known about the cellular component responsible for those fascinating 
observations. With the discovery of adipose tissue as a source for adipose-derived stem 
cells (ASCs), many of the advantageous effects observed after fat grafting were attributed 
to ASCs. Until now, the use of ASCs as a cell therapy for fibrosis has not been thoroughly 
investigated in clinical trials yet (McVicker and Bennett, 2017). In one study, ASCs were 
used to treat chronic ulcers in 10 patients with promising results showing improved healing 
(Akita et al., 2012). When ASCs were injected in soft tissue defects of 29 patients, reduced 
fibrosis and dermal scarring was observed (Tiryaki et al., 2011). More studies exist where 
ASCs have been used to enrich the lipograft, which is called cell-assisted lipografting (CAL). 
By the addition of ASCs, the graft survival shall be improved which was proven by various 
studies (Kølle et al., 2013, Tanikawa et al., 2013, Peltoniemi et al., 2013). Regarding the 
use of ASCs that have been cultivated in vitro before injection, only two clinical trials exist 
until now (Bura et al., 2014, Lee et al., 2012). Here, their use for critical limb ischemia has 
been explored, especially with the focus of revascularization. In both studies, ASCs were 
injected intramuscularly in patients who suffered from non-healing ischemic ulcers. The 
study of Bura and co-workers included 12 patients from whom 66.7% reported on ulcer 
healing after six months. In addition, reduced pain and increased mobility was observed. In 
the other study, four out of seven patients needed amputation after ASC injection. The three 
non-amputated patients described pain relief after six months. However, despite the 
amputations, no other side effects were reported in both studies. Interestingly, the improved 
ulcers in both studies were attributed to augmented angiogenesis by the administrated 
ASCs (van Dongen et al., 2018). Even though the ASC injection into ischemic ulcers 
showed benefits in both studies, large proportions of patients remained unaffected. The 
therapeutic effect of ASCs might be connected to a loss of ASCs via the circulatory or lymph 
system (Parvizi and Harmsen, 2015). Other factors that contribute to the therapeutic 
outcome are donor characteristics such as age and co-morbidity (Fossett et al., 2012). Also, 
the enzymatic isolation and cultivation of ASCs before injection could induce ASCs 
senescence (Gruber et al., 2012). Indeed, randomized, controlled large trials are necessary 






In animal models of wound healing, ASCs were tested for their regenerative potential as 
well. Interestingly, ASCs increased the healing rate of wounded areas and, after wound 
closure, less scarring was observed (Lam et al., 2012, Uysal et al., 2014). Lam and 
colleagues introduced ASCs to excisional wounds created in mice by using an ECM patch 
and observed improved wound healing rates. Moreover, ASCs improved healing of diabetic 
ischemic limbs in a diabetic nude mice model after injection (Kim et al., 2011). These in vivo 
data indicate that ASCs can prevent scar formation by accelerating wound healing. A 
comparison to the available clinical studies is difficult since wounds can be induced in 
animal models but the commonly used model organisms such as rats or mice do not 
develop pathological scars as observed in humans (see 4.2.).  
Having a look at in vitro studies, ASCs also show beneficial effects. An interesting study 
from Spiekman et al. revealed an inhibition of TGF-β mediated myofibroblast formation in 
the presence of CM from ASCs (Spiekman et al., 2014). Interestingly, another group 
working with myofibroblasts from Dupuytren’s disease obtained similar data indicating 
paracrine effects of ASCs (Verhoekx et al., 2013). All these different models and 
experimental settings provide valuable aspects on the regenerative potential of ASCs, 
however, concepts about the mode of action are still speculative.  
In contrast, thus far, the regenerative potential of other cellular components of adipose 
tissue such as adipocytes has rarely been studied. In fact, only a few studies have reported 
on the effects of adipocytes on wound healing (Hoerst et al., 2019). Among them, Schmidt 
and Horsley demonstrated that enhanced proliferation of adipocyte precursor cells and 
adipocyte repopulation in skin wounds after inflammation is crucial for adequate wound 
healing (Schmidt and Horsley, 2013). They used A-ZIP mice lacking all white adipose 
tissue, and thereby presented the importance of adipocytes for fibroblast recruitment and 
dermal reconstruction. Further studies focused on the primary adipokines adiponectin and 
leptin which seem to facilitate re-epithelialization (Salathia et al., 2013, Frank et al., 2000). 
For instance, in adiponectin-deficient mice wound re-epithelialization is severely delayed. 
By the addition of adiponectin to cultured keratinocytes, interestingly, cell proliferation and 
migration was enhanced and administration of adiponectin to mice skin wounds led to a 
faster wound healing rate (Jin et al., 2015, Shibata et al., 2012). Notably, similar effects 
were observed for leptin. Full-thickness skin wounds showed an accelerated re-
epithelialization and contraction when leptin was applied systemically or locally in leptin-
deficient mice (Frank et al., 2000, Ring et al., 2000). Even though there are several studies 
pointing towards a regenerative potential of adipocytes, more evidence and clarification is 
needed. Together with ASCs, two promising candidates for the observed scar regeneration 
exist, but knowledge about the determining factors and underlying mechanism is lacking. 




Hence, to study the regenerative potential of both ASCs and adipocytes, the effects of ASCs 
and in vitro differentiated adipocytes on myofibroblasts and on fibroblasts from hypertrophic 
scars were investigated in this thesis. Therefore, one first approach was to study the 
secretome of ASCs and adipocytes determined using mass spectrometry shot gut 
proteomics approach. Notably, data derived from a secretome analysis require careful 
interpretation because the results strongly depend on the experimental setup (Chevallet et 
al., 2007, Hoerst et al., 2019). Indeed, the analysis of secreted proteins represents a major 
challenge for current proteomic techniques. Low protein concentrations and contaminations 
from intracellular proteins released into the medium upon cell lysis are only two issues, to 
name a few. The main problem so far is, indeed, that various techniques for investigating 
the cell’s secretome exist, all with variable outcome (Chevallet et al., 2007). Therefore, a 
comparison of literature was conducted after the here performed analysis. Due to the 
complex functions of adipocytes, it was not surprising that we found more proteins secreted 
from adipocytes (288 proteins) than their precursors (160 proteins), which is also in line with 
comparative literature (Zhong et al., 2010, Ojima et al., 2016). Interestingly, 90 out of the 
288 identified proteins in adipocyte-CM have been previously found in the adipocyte 
secretome. In-depth analysis related to GO terms revealed that 23 of the proteins were 
associated with wound healing and 5 were associated with regeneration (Fig. 21), including 
collagen types 1, 3, and 5 and TIMP1, fibulin 1 and fibronectin 1 (Hoerst et al., 2019). A 
similar analysis was performed with the CM from ASCs, with the result that only 9 proteins 
can be assigned to wound healing and none to regeneration (Fig. 22). With only these two 
parameters in mind, protein amount and the GO terms wound healing and regeneration, 
this would indicate a higher regenerative potential from adipocytes than ASCs.  
In line with that, investigations of paracrine effects of adipocytes or ASCs on myofibroblasts 
resulted in similar speculations. Interestingly, incubation of myofibroblasts with adipocyte-
CM showed a significant reduction in the myofibroblast marker α-SMA as well as reduced 
expression of the ECM components collagen 1 and 3 (Fig. 15), indicating myofibroblast 
reprogramming or dedifferentiation. This effect was most pronounced in fibroblasts isolated 
from hypertrophic scars and superior to the effect of ASC-CM (Hoerst et al., 2019). For the 
latter, the regulatory effects on α-SMA expression have been previously demonstrated 
(Spiekman et al., 2014, Verhoekx et al., 2013, Li et al., 2016). Interestingly, the results of 
this thesis indicate stronger effects mediated by adipocytes compared to ASCs potentially 
due to the highly complex secretome of adipocytes. However, it has to be noted that this 
study has been working with in vitro differentiated adipocytes and the effect of mature 
adipocytes should be addressed in the future (Hoerst et al., 2019). Compared to mature 
adipocytes, in vitro differentiated adipocytes are smaller in size and never obtain the 






is a complex progress which requires the supplementation of an unphysiological hormonal 
cocktail (Siersbæk et al., 2012). Therefore, the secretome of in vitro differentiated 
adipocytes may vary from mature adipocytes. However, since the isolation and cultivation 
of mature adipocytes from adipose tissue is a difficult to handle process and limited in the 
amount of resulting viable adipocytes (Zhang et al., 2000), mature adipocytes were not 
isolated but in vitro differentiated from ASCs. Elaborating the question whether adipocytes 
or ASCs have a stronger impact on scar regeneration, more aspects of the in vivo situation 
need to be considered. A number of recent studies has focused on the fate of cells 
composing the fat graft after injection (Eto et al., 2012, Pu, 2016, Hong et al., 2018). 
Naturally, fat grafts require nutritional infusion until vascularization from the recipients site 
occurs. In the past, failed grafts showed loss of adipocytes and graft conversion into fibrotic 
tissue as well as oil cysts (Niechajev and Sevćuk, 1994). Due to shear stress and 
mechanical tension during the grafting procedure the large, fragile lipid-laden adipocytes 
are prone to cell death. Currently, two theories about the fate of the different cells in the fat 
graft exist: the “graft survival theory”, first described by Pu et al. considers graft survival 
trough imbibition until neovascularization in the recipient takes place (Pu, 2016). In contrast 
to this, the “graft replacement theory” describes another progress after graft application. Eto 
and co-workers presented the three-zone survival theory based on in vivo mouse studies 
(Eto et al., 2012). Here, inguinal fat pads were transplanted into scalped areas which were 
stained up to 14 days following procedure. They observed a surviving area where 
adipocytes were still viable, a regenerating area where adipocytes died but ASCs survived 
and replaced dead adipocytes by forming new ones, and the third, necrotic area where both 
adipocytes and ASCs died. From these observations they concluded that only a few 
adipocytes can survive the procedure, but the dead adipocytes are soon replaced by 
differentiating ASCs which were co-transplanted. Indeed, ASCs or preadipocytes are 20 
times smaller than adipocytes and thus, show a higher tolerance to ischemia (von Heimburg 
et al., 2005).This theory was supported by another study that also reported on adipogenesis 
and even angiogenesis by stromal cells (Fu et al., 2013). With regard to angiogenesis, Hong 
and colleagues demonstrated that injected ASCs can transform into endothelial cells (Hong 
et al., 2018). They also observed new fat formation by donor ASCs as well as recipient 
ASCs which would combine the “graft survival” and “graft replacement” theory. Also, the 
CM analysis in the present study supports the idea of ASC-mediated angiogenesis since 
ASC secrete proteins associated to angiogenesis (Fig. 22). The adipocyte secretome, in 
contrast, does not permit these considerations. Taking all these considerations into account, 
the obtained data from adipocytes and ASCs cannot be examined independently from each 
other. Even though adipocytes constantly induced stronger effects in myofibroblasts and 
hypertrophic scar fibroblasts in this in vitro study, this cannot be directly transferred to the 




in vivo situation. Here, ASCs would be necessary to form new adipocytes. Therefore, the 
interplay between the highly active, secretory adipocytes and resilient ASCs inducing 
adipogenesis and angiogenesis might be responsible for implementing the regenerative 
potential of adipose tissue. In addition, it should be mentioned that other cell types residing 
in the SVF, such as pericytes, macrophages and endothelial cells, may also contribute to 
tissue regeneration which have not been considered in the present study. 
Despite all the advantageous and impressive reports and studies regarding autologous fat 
grafting, there are also concerns about the use of this technique. Since fat transfer methods 
as well as isolation procedures and cultivation conditions in vitro are still highly variable, 
uniform procedures are required. Until now, fat grafting may lead to unpredictable clinical 
outcomes in terms of graft take and viability confirming the need for well-designed placebo-
controlled clinical trials (Longaker et al., 2014). While the positive results of fat grafting on 
wound healing and fibrotic conditions have been investigated in small-scaled studies and 
reports only, the therapeutic effect needs to be corroborated in controlled trials (van Dongen 
et al., 2018). Especially specific applications for fat grafting such as breast reconstruction 
after breast cancer must be evaluated carefully. Here, particularly ASCs are discussed 
controversially since those cells may increase the risk for cancer recurrence (Bielli et al., 
2014, Massa et al., 2015, Ito et al., 2017).  
As became evident in this chapter, adipose tissue and its cellular components revealed 
improvements in various wound healing models and showed positive findings on scarring. 
Unfortunately, the underlying mechanism is often not addressed or leaves room for 
speculations. Therefore, the present situation in combination with findings of this thesis will 







4.3. Insights into the Mechanisms of Scar Regeneration 
Since myofibroblasts represent one of the key cell types during wound healing and their 
persistent activity is associated with the occurrence of fibrosis, the fate of myofibroblasts in 
fibrotic tissue following fat injections is of great interest. 
At the beginning of this study, when adipocyte-CM was applied onto myofibroblast, a 
significant reduction in myofibroblast characteristics was observed (Fig. 15). These 
characteristics comprised the myofibroblast marker α-SMA and the ECM production of 
collagen 1 and 3 due to the lack of other valuable marker for this cell type (1.1.3). CM 
incubation on hypertrophic scar fibroblasts, that were used as an additionally primary source 
from scar tissue, resulted in an even stronger downregulation of those characteristic 
proteins. In addition, the contractility of the myofibroblast phenotype was tested in a 
collagen lattice, with the similar result that myofibroblast contraction was diminished in the 
presence of adipocyte-CM (Fig. 16). Following those first promising results, further insights 
into intracellular signaling cascades in the myofibroblast were gained. Due to its pivotal role 
in myofibroblast formation and persistence, canonical and non-canonical TGF-β signaling 
pathways were investigated upon CM-incubation. These data indicate the occurrence of 
Smad-independent changes in TGF-β signaling because the MAPKs ERK and p38 
exhibited reduced phosphorylated expression in adipocyte-CM-treated myofibroblasts and 
hypertrophic scar fibroblasts (Fig. 19). This is in line with previous literature. Although the 
Smad3 pathway is considered as one of the major fibrotic inducers, other studied revealed 
essential roles of ERK and p38 in models of fibrosis (Pannu et al., 2007, Stambe et al., 
2004).  
The α-SMA reduction seems to be at least partially mediated by PPARγ receptor activation 
because no α-SMA downregulation was observed when PPARγ was blocked (Fig. 20). 
Interestingly, previous studies have reported anti-fibrotic effects of PPARγ induced by 
attenuation or even inhibition of TGF-β signaling (Ghosh et al., 2004, Burgess et al., 2005, 
Aoki et al., 2009). More precisely, PPARɣ activation by naturally occurring or synthetic 
agonists suppressed profibrotic responses induced by TGF-β. For instance, the PPARɣ 
ligand 15d-PGJ2 dose-dependently attenuated TGF-β-mediated production of connective 
tissue growth factor or ECM products such as fibronectin in hypertrophic scar fibroblasts 
(Zhang et al., 2009). Moreover, the PPARɣ agonist rosiglitazone prevented the 
development of skin fibrosis in a model of bleomycin-induced scleroderma (Wu et al., 2009). 
So far, the underlying mechanisms of the TGF-β-antagonizing effect of PPARγ are not 
completely defined. An upregulation of the tumor suppressor phosphatase and tensin 
homolog (PTEN) was considered as an anti-fibrotic mediator since PTEN has been shown 
to inhibit α-SMA and other TGF-β target genes in mouse fibroblasts (White et al., 2006, Lee 




et al., 2006). Apart from that, the inverse relationship to TGF-β involving a suppression of 
PPARɣ by enhanced TGF-β activity provides more clues. Notably, reduced PPARγ 
expression and enhanced TGF-β signaling is associated with progressive fibrogenesis (Wei 
et al., 2010, Hoerst et al., 2019). Interestingly, one study revealed a TGF-β activated Smad 
repressor complex that induces PPARɣ downregulation at the transcriptional level. The 
authors showed histone deacetylation in the PPARɣ promotor after binding of the repressor 
complex to specific regulatory elements (Lakshmi et al., 2017). In the present study, 
subfractionation of CM-treated myofibroblasts increased the PPARγ expression in 
cytoplasmic and nuclear fractions (Fig. 20). Interestingly, high-throughput protein analysis 
showed an upregulation of CITED2 in myofibroblasts after incubation with adipocyte-CM 
(Fig. 26). CITED2 is a transcriptional activator for both TGF-β and PPARγ (Chou et al., 
2006, Tien et al., 2004), and it may be speculated that both TGF-β-dependent Smads and 
PPARγ compete for the same pool of CITED2 molecules for efficient target gene activation 
(Hoerst et al., 2019). In addition, the high-throughput analysis also compromised proteins 
involved in Wnt signaling. Notably, Wnt signaling is a third component that has been shown 
to interact both with TGF-β and PPARɣ (Vallée et al., 2017). The inhibitory effects of the 
Wnt family on PPARɣ were already recognized in 2000 (Ross et al., 2000). In a study of 
Macdougald and colleagues the anti-adipogenic effect of Wnts by PPARɣ suppression was 
shown. Thereby, Wnt family members can shift an adipogenic program towards the 
osteoblastic lineage in bone marrow-derived stem cells (Takada et al., 2007). In the present 
study, regulated Wnt signaling through CM stimulation would present a reasonable 
explanation of the observed impact of PPARɣ and was, therefore, investigated in 
myofibroblasts but showed no clear results (Fig. 26). Even though the Dickkopf-related 
protein 1 (DKK-1), which is known to be involved in the inhibition of the Wnt pathway, was 
increased, however, other proteins such as c-myc were upregulated, thus indicating Wnt 
activation. Therefore, these opposing results give no clear indication about Wnt activity. 
Altogether, these results indicate that direct as well as indirect activation of PPARɣ signaling 
shifts the balance toward anti-fibrotic effects (Fig. 29) (Hoerst et al., 2019). However, thus 
far, the component of adipocyte-CM that directly activates the PPARγ receptor is unknown 
and so is the specific mechanism between PPARɣ and TGF-β activities. 
Although the decreased expression levels of α-SMA and collagen 1 and 3 indicate a 
dedifferentiation of myofibroblasts, their specific fate remains to be elucidated, which is 
challenging because specific markers to characterize and distinguish myofibroblasts and 
fibroblasts have not yet been identified (Hoerst et al., 2019). A recent study from Plikus et 
al. reported myofibroblast reprogramming into the adipogenic lineage induced by BMP-2 
and BMP-4 secreted from hair follicles during wound healing in mice (Plikus et al., 2017). 






fibroblasts (Hoerst et al., 2019). Interestingly, the authors observed a fibroblast-to-adipocyte 
in vitro differentiation in keloid fibroblasts but could not induce a similar conversion of 
hypertrophic scar fibroblasts. Inspired by the Plikus study, the influence of BMPs in this 
project was investigated. Notably, BMP-4 was secreted by adipocytes, and inhibition of 
BMP receptor type I abolished the reduction in α-SMA expression in myofibroblasts, 




Fig. 29: Paracrine effectors secreted by adipocytes trigger myofibroblast reprogramming via 
BMP-4 secretion and PPARγ activation. 
Schematic depiction of the cellular crosstalk between adipocytes and myofibroblasts. Usually 
myofibroblasts are triggered by transforming growth factor (TGF)-β1 during wound healing mediating 
target gene expression such as α-smooth muscle actin (α-SMA) via canonical (SMAD 2/3) and non-
canonical (ERK, p38) signaling pathways (highlighted in grey). Upon fat grafting, adipocytes 
secreting bone morphogenetic protein (BMP-4) induce peroxisomal proliferator-activated receptor 
(PPAR)γ activation in myofibroblasts leading to target gene expression and anti-fibrotic effects. 
TGFR = TGF-receptor; BMPR = BMP receptor; RXR = retinoid X receptor. (Hoerst et al., 2019)                  
 




Moreover, DigiWest® analysis showed enhanced BMP-4 protein expression in 
myofibroblasts following stimulation with adipocyte-CM (Fig. 27), which is in line with recent 
findings in human esophageal myofibroblasts (Zhang et al., 2018). Members of the BMP 
family, especially BMP-2, 4, and 7, are known for their anti-fibrotic potential by opposing the 
actions of TGF-β signaling (McVicker and Bennett, 2017, Shlyonsky et al., 2011, Pegorier 
et al., 2010). However, in contrast with Plikus et al., an adipogenic differentiation of 
myofibroblasts or hypertrophic scar fibroblasts (Fig. 24) could not be induced (Hoerst et al., 
2019). Since Plikus and colleagues were also not successful in trans-differentiating 
hypertrophic scar fibroblasts, keloid fibroblasts were included in this study. However, also 
here no adipocytes were formed. Although the experimental setting (48h BMP-4 stimulation 
for adipogenic commitment, followed by 10 days of adipogenic differentiation medium) was 
copied from Plikus et al., some parameters varied such as the adipogenesis medium 
composition which was kept as used in this study before. In addition, minor other factors 
may have differed which were not provided in their publication. Apparently, diverse factors 
such as experimental duration, medium supplements and serum content all contribute to a 
cell’s behaviour in vitro and therefore, primary cell culture experiments are difficult to 
reproduce and prone for variations. Nevertheless, even though no phenotypical change with 
the formation of lipid droplets was observed, some data may indicate the onset of 
adipogenic differentiation because increased CEBPβ expression and activation of BMP-
4/SMAD 1/5/9-signaling, both of which are key activators of adipogenesis, were found in 
myofibroblasts after incubation with adipocyte-CM (Fig. 27) (Hoerst et al., 2019). In addition, 
a time-course gene expression analysis revealed an upregulation of PPARɣ as well as the 
BMP targets Id1 and Zfp423 following BMP-4 stimulation (Fig. 25). Interestingly, adipocyte-
CM induced similar results although to a less extent. These results are in line with recent 
data demonstrating enhanced expression of PPARγ in 3T3-L1 adipocytes (Schreiber et al., 
2017) and differentiation of precursor cells into the adipocyte lineage (Huang et al., 2009, 
Hammarstedt et al., 2013) after incubation with BMPs. However, further studies are 
necessary to draw final conclusions. Here, the experimental setting needs to be considered 
and perhaps modified. The CM studies were conducted for 24h only, which appeared to be 
sufficient for a reduction of characteristic protein expression (Fig. 15). However, the 
transformation of one cell type into another lineage, which was shown by Plikus et al., 
potentially needs more time. Their in vitro study was conducted for a total of 12 days which 
was enough at least for a conversion of keloid fibroblasts. Notably, the high-throughput 
protein analysis performed in the present study provided evidence that myofibroblast 
characteristics are still present, as indicated by the high expression levels of PAI-1 or Notch-






Therefore, more insights into the protein expression level of CM-treated myofibroblasts are 
required and might benefit from further knowledge about their transcriptional control. 
Since an adipogenic conversion of myofibroblast could not be proven, another assumption 
for the myofibroblast fate after fat injection is a redifferentiation back to fibroblasts. Since 
the annexin V/PI staining was negative (Fig. 17), apoptosis and thus, disappearance of 
myofibroblasts in the fibrotic tissue, can be excluded. Interestingly, several studies reported 
that myofibroblasts can disappear by a reversal of the differentiation (Hecker et al., 2011, 
Wettlaufer et al., 2016, Horowitz and Thannickal, 2018). One study proposed the role of the 
transcription factor MyoD in the dedifferentiation of TGF-β induced lung fibroblasts. Here, 
MyoD downregulation mediated by ERK signaling was demonstrated in myofibroblast 
deactivation (Hecker et al., 2011). Another group showed that the lipid mediator 
prostaglandin E2 was able to induce dedifferentiation in a lung fibroblast cell line treated 
with TGF-β (Wettlaufer et al., 2016). These data support the concept that myofibroblast are 
not terminally differentiated cells, however, the reversibility of this phenotype is so far not 
completely understood. 
Overall, the data of the present study addressing mechanisms of scar regeneration indicate 
that adipocytes can induce myofibroblast reprogramming. These paracrine effects are 
mediated by direct and indirect activation of PPARɣ signaling as well as by the release of 
BMP-4 and subsequent stimulation of BMP signal transduction; both of these signaling 
pathways are known for their TGF-β-antagonizing and hence anti-fibrotic effects (Fig. 29) 
(Hoerst et al., 2019).  
Although the important and unique role of myofibroblasts in wound healing and scar 
processes is indisputable, it might be speculated whether the complex progress of scar 
remodeling can be attributed to a myofibroblast conversion only. As described before, 
angiogenesis could play a key role as well. Since ASCs are often mentioned in this context 
(Fig. 22, (Dong et al., 2015, Li et al., 2003)), this presumption is not far-fetched. One aspect 
why angiogenesis seems to be critical in scar regeneration is the need for new blood vessel 
formation to guarantee fat graft survival. Since this can be provided not only by the recipient 
site but also by ASCs (Kachgal and Putnam, 2011), endothelial cells (Koh et al., 2011) and 
potentially also adipocytes (Park et al., 2001) originating from the injected adipose tissue, 
the graft might exert further pro-angiogenic functions on promoting scar improvement 
(Javazon et al., 2007). However, whether enhanced angiogenesis is beneficial for a 
reduction of scar appearance remains questionable. Several studies suggest contradictory 
effects since pronounced angiogenesis was associated with scar formation (Diao et al., 
2010, Gira et al., 2004, Wilgus et al., 2008). Interestingly, systemic administration of the 




anti-angiogenic endostatin reduced hypertrophic scarring in a rabbit ear model (Ren et al., 
2013). Overall, more evidence for pro- and anti-angiogenic effects on pathological scars is 
needed and must be assessed carefully.  
In addition to angiogenesis, other aspects such as ECM remodeling in scar reduction need 
to be evaluated more extensively. With considering all the different factors potentially 
involved in tissue regeneration, again suitable models need to be addressed as being 
crucial. Due to the lack of relevant models, mechanistic studies on the regenerative potential 
of adipose tissue on native scar remodeling specifically are underrepresented. Existing 
studies have mainly focussed on wound healing acceleration or inhibition of scar formation 
by fat graft components. Insights into those processes are of great importance but effects 
and mechanisms in pre-existing scars and their transformation may vary widely.  
 
4.4. Conclusion 
With this study, more insights into the complex intercellular crosstalk of adipose tissue and 
scar tissue were gained. These data demonstrate the regenerative potential of adipocytes 
and provide new insights into the regenerative processes triggered by autologous fat 
grafting. Here, the importance and contribution of adipocytes to scar regeneration was 
highlighted. The effect of adipocytes over ASCs was superior, however, the transferability 
of these results to the in vivo situation remains questionable since adipocytes and ASCs 
behaviour in their natural habitation might result in a different clinical outcome. Raising the 
point of an applicable and adequate model for studying intracellular signaling pathways, the 
chosen approach of the in vitro co-cultivation of myofibroblasts and hypertrophic scar 
fibroblasts with conditioned medium of adipocytes indeed presented a suitable model for 
studying intracellular signaling pathways. By addressing TGF-β signaling, an interesting, 
reciprocal relationship with the nuclear receptor PPARɣ became clear. Even though the 
mechanism of PPARɣ activation by secreted factors of adipocytes requires further 
investigation, a pivotal role of BMP-4 in this regard was considered in this study. A trans-
differentiation of myofibroblasts would provide a reasonable explanation for the 
observations made on scar regeneration in vitro and in vivo but, however, this could not be 
confirmed in this study. Even though the specific fate of myofibroblasts remains to be 
elucidated, an initiated myofibroblast reprogramming was clearly shown. A more detailed 
understanding of these mechanisms may pave the way toward novel strategies for scar 








The complex contributing factors underlying scar remodelling remain challenging for 
clinicians, dermatologists and researchers. While both processes before and after 
treatment, the development and progression of pathological scars as well as their positive 
transformation upon fat injection, are only understood to some degree, ideal treatment and 
prevention options for abnormal scars are far from optimal. Since human studies on the one 
hand have their ethical restrictions and are difficult to achieve, animal studies on the other 
hand provide only little potential to extrapolate findings to the human situation (see 0), the 
focus should be on in vitro studies. The presented two-dimensional approach in this study 
provides a valuable tool for studying intracellular changes in the myofibroblast and 
hypertrophic scar fibroblasts. So far, only ASCs and adipocytes have been tested for their 
regenerative potential in this setting. Therefore, it remains open to what extent other cell 
types of the stromal vascular fraction (SVF) such as pericytes, endothelial cells, 
macrophages etc. residing in the autologous fat grafts may also contribute to myofibroblast 
dedifferentiation. This requires specific attention since BMP-4 production, for example, has 
been recently shown in endothelial cells (Wertheimer et al., 2018). However, these aspects 
were beyond the focus of the current work but clearly require further attention in future 
investigations (Hoerst et al., 2019). In addition, further attention should be drawn on the 
actual mediator of PPARɣ activation. Notably, one recent discovery in the field of cell-cell 
communications are exosomes. Exosomes are extracellular vesicles secreted by cells and 
may contain proteins, lipids, mRNAs or microRNAs (miR). This content can be transferred 
to an acceptor cell and may have functional effects in those recipient cells. With regard to 
adipose tissue, a fascinating study recently provided more insights. Ying and colleagues 
studied the exosome profile of adipose tissue macrophages in obese mice and found 
exosomes containing miR-155 (Ying et al., 2017). Interestingly, miR-155 has been shown 
to be a target of PPARɣ (Chen et al., 2013, Han et al., 2018). Moreover, Ying et al. 
demonstrated that miR-155 knockout mice are insulin sensitive and glucose tolerant. 
Although the survey of adipose tissue-derived miRs has already started (Thomou et al., 
2017), more extensive studies on the adipose tissue secretome profile, especially with 
regard to its effects on PPARɣ activation and expression in myofibroblasts, are inevitable. 
Returning to the question of suitable in vitro models, more advances in establishing a scar 
regeneration model are necessary. The presented 3D model in this study is, indeed, quite 
simple but showed first favorable results. By integrating a layer of adipocytes, the most 
promising cell type concluded from the here obtained results, the model would already 
benefit with regard to complexity. Indeed, other cell types such as keratinocytes or 
endothelial cells would be necessary, too. As mentioned before (0), the organ-on-a-chip 




technology would provide a promising tool integrating all these different cell types. In 
addition to 3D models, human skin biopsies might contribute to gain more insights about 
scar remodeling as well. If it were possible to obtain scar biopsies before and after fat 
injection, cellular and histological changes in the excised tissue could be observed right 
away. Getting access to such biopsies, indeed, would be challenging but the expected data 
would be more than promising. An aspect that has not been mentioned before, is the type 
of adipose tissue being used for studying scar regeneration. Naturally, the adipose tissue 
that is harvested and injected in plastic surgery is subcutaneous white adipose tissue. The 
fact that the human body also comprises brown and brite adipose tissue should be included 
in future considerations dealing with scar remodeling. Since brown and beige adipose tissue 
holds promising potential their effect on scar regeneration could provide valuable 
knowledge on regenerative possibilities. Interestingly, brown adipose tissue was discovered 
as an endocrine organ as well (Villarroya et al., 2017). Therefore, a comparison of secretory 
factors released by brown and white adipocytes with regard to tissue remodeling could 
provide new, promising insights. 
Overall, the investigation of adipose tissue mediated-scar regeneration needs further 
standardized methods with regard to secretome analysis and in vitro model generation. 
Once the complete secretome of adipocytes is accessible and suitable complex cell-based 
models are available, lacking evidence might be provided for the remaining open questions 
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Fig. 30: Annexin V/PI staining of the DMSO-treated samples according to Fig. 17.  
DMSO-treated myofibrbolasts were either stained with Annexin V (a) or incubated with PI (b) and 
subjected to flow cytometry. 
 
 
Table 4: List of proteins found in mass spectrometry including their score and peptide number. 
Proteins associated with GO term 0042060 (wound healing) are marked with 1. Proteins associated 
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 129.4 26 30 38 
PGBM Basement membrane-
specific heparan sulfate 
proteoglycan core 
protein  
 329.6  509.6  551.1 11 34 41 
CO4A2 Collagen alpha-2(IV) 
chain  
 528.5  358.5  142.6 18 15 25 
NID1 Nidogen-1   959.4  260.7  574.4 16 17 19 




11 16 23 
TENA2 Tenascin   237.2  133.2  354.8 5 12 31 
TSP11 Thrombospondin-1   888.7  987.2 1298.
8 
14 12 22 
A2MG1 Alpha-2-macroglobulin   763.6  498.9  768.1 17 13 15 




 503.9 8 13 23 
TSP2 Thrombospondin-2   361.8  448.8  591.7 11 15 16 
CO31 Complement C3   967.4  543.9  886.3 12 14 13 
GELS1,2 Gelsolin   404.9  443.4  514.8 10 12 10 




COMP Cartilage oligomeric 
matrix protein  
1159.
0 
 629.8  976.6 12 9 10 
ACTN41 Alpha-actinin-4     68.3  602.0  873.0 4 12 14 
CO5A11 Collagen alpha-1(V) 
chain 
 311.6  686.0  252.4 7 11 11 
LDHA L-lactate 





11 8 9 
BGH3 Transforming growth 
factor-beta-induced 
protein ig-h3  
   84.7 1227.
3 
 671.7 4 10 13 




 721.0 5 8 14 
VINC1 Vinculin   221.6  371.7  690.6 8 4 14 
PAI11 Plasminogen activator 
inhibitor 1  
 198.0  786.8  142.2 3 10 12 
LAMA4 Laminin subunit alpha-4   199.5  227.5  168.0 5 7 12 
ENOA Alpha-enolase  776.6  975.5 1032.
3 
8 5 10 
C1R Complement C1r 
subcomponent 
 373.9    93.3    79.1 6 7 7 
LAMB1 Laminin subunit beta-1  
 
 107.8    56.6 
 
7 11 
C1S Complement C1s 
subcomponent  
   21.5  357.4  234.9 1 9 7 
LG3BP Galectin-3-binding 
protein  
   71.3  135.9  107.5 4 6 7 
DPYL2 Dihydropyrimidinase-
related protein 2  
 128.8  267.9  112.0 6 5 6 
FBLN11 Fibulin-1  
 
 188.6  161.6 
 
8 9 
LAMC1 Laminin subunit gamma-
1 
   19.0    96.7  146.2 1 7 8 
LUM Lumican  759.4  373.3  411.9 4 7 5 
PGK1 Phosphoglycerate 
kinase 1  
 142.1  535.4  623.9 4 4 8 
NID2 Nidogen-2  130.9    46.1    67.0 5 5 6 
SPRC1 SPARC   214.0  903.1  499.9 6 5 5 
CALU1,2 Calumenin  
 
 293.0  293.4 
 
10 6 
FSTL1 Follistatin-related protein 
1  
 277.2  527.7  423.2 6 4 5 
ALDOA1 Fructose-bisphosphate 
aldolase A  
 203.2  503.2  382.1 7 4 4 
PDIA3 Protein disulfide-
isomerase A3  
   77.6  317.5  126.6 5 7 2 
TPM4 Tropomyosin alpha-4 
chain  
 213.7  220.4  303.3 5 4 5 






 589.4 6 3 5 
CALR Calreticulin   103.6  725.4  485.9 3 6 4 
TAGL Transgelin     39.9  280.9  249.9 3 3 7 
LDHB L-lactate 
dehydrogenase B chain  
 127.2  192.2  109.1 4 5 3 
PPIA1 Peptidyl-prolyl cis-trans 
isomerase A  
 201.9  690.0  570.8 2 4 5 





COF11 Cofilin-1   169.2  360.8  375.4 4 4 3 
PGAM1 Phosphoglycerate 
mutase 1  
 109.5  152.0  133.8 4 4 3 
MOES Moesin     89.2  335.7  259.1 4 2 5 
IBP7 Insulin-like growth 
factor-binding protein 7  
   42.8  225.0  195.6 1 4 5 
PRDX1 Peroxiredoxin-1     51.5  136.9  100.4 4 2 4 
PROF11 Profilin-1   200.1  335.3  302.5 4 3 3 




CYTC Cystatin-C  
 




transferase P  





   62.8  120.4 82.3 3 3 3 
FABP4 Fatty acid-binding 
protein, adipocyte 




SPTN1 Spectrin alpha chain, 
non-erythrocytic 1 
 
   99.5    55.9 
 
2 7 
FBLN2 Fibulin-2     17.6  119.6  279.0 1 4 3 
PGS1 Biglycan     22.9  146.3    13.2 1 4 3 
KPYM1,2 Pyruvate kinase PKM     70.7  724.5  326.6 3 2 3 
FAS Fatty acid synthase   190.4 1189.
3 
   30.9 4 5 4 
COTL1 Coactosin-like protein    37.7  229.3  258.7 3 2 2 
HSPB11 Heat shock protein beta-
1 
   54.3  214.2  152.8 3 1 3 




FBLN5 Fibulin-5  
 
30.5    28.0 
 
3 4 
CSTN1 Calsyntenin-1  
 
   33.8    91.9 
 
2 3 
PSA7 Proteasome subunit 
alpha type-7 
   87.0  112.0    91.5 1 1 3 
TIMP11 Metalloproteinase 
inhibitor 1  
   29.0  169.7  285.6 1 2 2 
RLA2 60S acidic ribosomal 
protein P2  
   92.2  164.7  124.3 1 1 3 




B2MG Beta-2-microglobulin  
 
   94.1    26.2 
 
2 3 
MDHC Malate dehydrogenase, 
cytoplasmic 
   27.1  124.7    90.9 1 1 2 
ZYX Zyxin  
 
   24.6    24.8 
 
1 2 
SODM Superoxide dismutase 
[Mn], mitochondrial 
   25.0    25.6    37.3 1 2 1 
RL10A 60S ribosomal protein 
L10a  
   21.9    26.8    29.3 1 1 1 
P4HA1 Prolyl 4-hydroxylase 
subunit alpha-1 
 
   79.2 38.4 
 
2 1 
CATB Cathepsin B 
 
   44.8 45.3 
 
1 2 
PLEC Plectin  
 






   81.4 
 
   78.1 1 
 
1 




HNRPF Heterogeneous nuclear 
ribonucleoprotein F  
   34.0 
 
   68.1 1 
 
1 
IBP6 Insulin-like growth 
factor-binding protein 6  
 
   34.0 34.1 
 
1 1 
NPM Nucleophosmin  
 
   76.7    23.7 
 
1 1 
MDHM Malate dehydrogenase, 
mitochondrial  
 
   53.9 32.8 
 
1 1 
THIO Thioredoxin  
 
   64.0    67.1 
 
1 1 
FABP5 Fatty acid-binding 
protein, epidermal  
 
   64.8 24.0 
 
1 1 
IF5A1 Eukaryotic translation 
initiation factor 5A-1  
 
 295.3  135.7 
 
1 1 
PSB3 Proteasome subunit 
beta type-3  
 




Table 5: List of proteins found in mass spectrometry including their score and peptide number. 
Proteins associated with GO term 0042060 (wound healing) are marked with 1. Proteins associated 
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58 27 44 
CO3A11 Collagen alpha-1(III) 
chain  






4340.2 1144.4  614.6 52 36 35 
CO4A22 Collagen alpha-2(IV) 
chain  
 729.0  191.3    25.3 12 11 10 
TSP12 Thrombospondin-1  3429.5 1572.3  335.7 39 8 11 
CO6A1 Collagen alpha-1(VI) 
chain  
2181.9 1167.1  391.6 22 18 15 
TSP2 Thrombospondin-2  1173.9 1075.0    68.0 11 3 9 
CO5A11 Collagen alpha-1(V) 
chain 
2111.3  886.6  309.6 34 8 22 
CO6A3 Collagen alpha-3(VI) 
chain  




1608.0 1179.1  779.6 12 11 20 
PTX3 Pentraxin-related 
protein PTX3  
1049.9 2101.2  481.3 10 12 8 
ANXA22 Annexin A2  2856.6 1170.3  353.2 18 12 12 
MMP22 72 kDa type IV 
collagenase  
 509.0  160.1    42.2 6 4 9 
PAI12 Plasminogen 
activator inhibitor 1  
 513.0    32.2  323.8 8 4 12 
CO6A2 Collagen alpha-2(VI) 
chain 
 853.2  237.2    75.6 12 6 8 
CO5A2 Collagen alpha-2(V) 
chain 





GDN1 Glia-derived nexin  338.5 
 
   30.0 12 
 
5 
C1S Complement C1s 
subcomponent  
 348.2  486.1  136.5 8 7 9 
FBLN11 Fibulin-1  
 
 792.8  152.5  100.3 11 5 
LAMC1 Laminin subunit 
gamma-1 





   51.0 3 
 
SPRC1 SPARC  
 
 269.7  152.5    50.6 8 5 
CALU Calumenin  
 
 772.8  131.4  118.8 12 13 
FSTL1 Follistatin-related 
protein 1  
1707.4 1652.3  394.4 7 4 4 
PDIA3 Protein disulfide-
isomerase A3  
 560.8    38.5    57.7 13 5 9 
CALR Calreticulin  1519.1  132.4  106.0 8 5 5 
TAGL Transgelin  
 
 394.4    24.7    29.0 6 4 
SVEP1 Sushi, von Willebrand 
factor type A, EGF 
and pentraxin 
domain-containing 
protein 1  
1101.8 
 






protein 1  
1392.2  440.0    98.9 5 5 6 
IBP7 Insulin-like growth 
factor-binding protein 
7  
 812.2  227.0    67.4 5 5 3 
CYTC Cystatin-C  
 




rich repeat protein  
 533.9  684.1    27.0 4 4 5 
FBN1 Fibrillin-1  
 
 222.2  573.5    61.8 3 5 
QSOX1 Sulfhydryl oxidase 1   595.1  519.3    60.7 9 6 7 
LEG1 Galectin-1  
 
 736.5    38.6    34.2 4 3 





inhibitor 1  
 316.6  298.4    82.7 2 2 2 
CLUS Clusterin  
 
   31.7    27.0    68.8 4 2 
TIMP2 Metalloproteinase 
inhibitor 2 
   42.9  178.8  166.6 3 2 2 
  




Table 6: List of proteins analyzed in DigiWest® profiling including expression levels and antibody 
information. 
Analyte Log2 Ratio CM vs. Ctrl Supplier 
 Group 1 Group 2 Group 3  
14-3-3 epsilon 0,588 0,187 0,285 Cell Signaling Technology 
14-3-3 sigma 0,879 0,116 0,368 R&D 
4E-BP1 0,233 -0,234 -0,105 Abcam 
4E-BP1 - phospho 0,653 0,353 0,082 Cell Signaling Technology 
Adam9 0,990 0,884 1,107 Cell Signaling Technology 
Bax 0,651 0,146 0,445 Cell Signaling Technology 
Bcl2 0,676 -0,516 0,000 Cell Signaling Technology 
beta-Catenin -0,127 0,317 0,103 Cell Signaling Technology 




-0,233 0,810 0,136 Cell Signaling Technology 
Bip -0,067 1,448 1,228 Cell Signaling Technology 
BMP4 1,576 1,554 0,232 Abcam 
Brachyury 0,369 1,626 1,058 Thermo Fisher Scientific 
C/EBP-β 0,203 0,498 0,780 Cell Signaling Technology 
Caveolin-1 -0,247 -0,116 -0,106 Cell Signaling Technology 
CBP 0,000 0,189 0,748 Cell Signaling Technology 
CITED2 0,000 0,345 0,121 Abcam 
c-Jun -0,122 -0,031 -0,284 Cell Signaling Technology 
c-Jun - phospho 0,000 0,986 0,112 Cell Signaling Technology 
c-myc [61kDa] -1,836 0,076 -0,176 Cell Signaling Technology 
c-myc - phospho 0,000 0,000 0,089 Abcam  
CREB -0,848 0,796 0,200 Cell Signaling Technology 
CREB - phospho -0,666 0,118 -1,026 Cell Signaling Technology 
DKK1 [35kDa] -0,583 0,420 0,267 Biorbyt 
E2F-4 -0,008 -0,338 -0,149 Biorbyt 
Erk1/2 (MAPK p44/42) 
[42kDa] 
0,566 0,129 0,453 Cell Signaling Technology 
Erk1/2 (MAPK p44/42) 
[47kDa] 
0,173 -1,157 0,440 Cell Signaling Technology 
Erk1/2 (MAPK p44/42) - 
phospho [42kDa] 
-1,118 -1,647 -1,409 Cell Signaling Technology 
Erk1/2 (MAPK p44/42) - 
phospho [48kDa] 
-0,667 -1,561 -1,588 Cell Signaling Technology 
FABP4 -1,208 1,091 0,000 Cell Signaling Technology 
FAK 0,099 0,282 0,118 Cell Signaling Technology 
FAK - phospho -0,102 0,077 -0,036 Cell Signaling Technology 
FAK1 -0,059 0,693 0,017 Abcam 
FKBP12 0,592 -0,525 -0,287 Abcam 
FRA1 - phospho -0,749 -0,760 -1,827 Cell Signaling Technology 
GDF3 1,093 -0,060 -0,011 Abcam 
GDF8 (Myostatin) -0,774 0,669 0,076 Abcam 





HNF-4 alpha 0,069 -0,203 -0,047 biorbyt 
HNF-4 alpha - phospho -0,630 -0,963 0,141 biorbyt 
HSP70 0,365 0,016 -0,046 Cell Signaling Technology 
JNK/SAPK [46kDa] 0,634 0,032 -0,186 Cell Signaling Technology 
JNK/SAPK [54kDa] 0,441 -0,372 0,021 Cell Signaling Technology 
JNK/SAPK 1/2/3 - 
phospho 
0,000 -0,064 -0,213 Abcam 
LEF1 0,000 0,000 -0,496 Cell Signaling Technology 
Lipoprotein lipase 0,066 0,000 0,000 Abcam 
MAPK/CDK substrates -0,538 0,156 -0,444 Cell Signaling Technology 
Notch 1 0,246 0,926 0,406 Cell Signaling Technology 
p38 MAPK 0,739 0,137 -0,352 Cell Signaling Technology 
p70 S6 kinase 0,335 0,130 -0,009 Cell Signaling Technology 
p70 S6 kinase - phospho -0,322 0,278 -0,614 Cell Signaling Technology 
PAI-1 0,573 0,813 1,604 Cell Signaling Technology 
PARP [116kDa] -0,229 0,974 0,227 Cell Signaling Technology 
PARP [89kDa] 0,000 0,299 0,000 Cell Signaling Technology 
Paxillin [60kDa] -0,290 0,277 -0,046 Abcam 
p- Smad 2/3 0,578 0,272 0,748 Cell Signaling Technology 
PP2A C - phospho -1,170 0,126 -0,258 R&D 
PP2A C 0,381 -0,041 -0,027 Cell Signaling Technology 
PPAR gamma -0,240 -0,166 -0,142 biorbyt 
 
Ras -0,283 0,376 -0,309 Cell Signaling Technology 
SFRP2 0,000 0,333 0,465 Abcam 
 
Smad1 0,197 0,627 0,396 Cell Signaling Technology 
Smad2/3 0,176 0,285 0,383 Cell Signaling Technology 
Smad4 0,475 0,662 0,746 Cell Signaling Technology 
Smad5 0,797 -0,192 -0,842 Cell Signaling Technology 
Src 0,024 0,408 0,294 Cell Signaling Technology 
Src - phospho -0,253 0,289 -0,129 Cell Signaling Technology 
Src family - phospho -0,856 0,615 0,108 Cell Signaling Technology 
TACE -1,433 -0,652 -0,377 Cell Signaling Technology 
TAK1 0,434 0,371 -0,559 Cell Signaling Technology 
Vimentin -0,130 0,214 -0,132 Cell Signaling Technology 
Vimentin - phospho 0,031 0,634 -0,353 Cell Signaling Technology 
14-3-3 zeta delta -0,550 -0,076 0,363 Cell Signaling Technology 
Vimentin - phospho -0,387 -0,159 -0,439 Cell Signaling Technology 
 
 
 
